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Abstract 
Most tumor cells are characterized by elevated glucose uptake and use. In order to 
meet the increased energy demand during tumor development, cancer cells synthesize 
more glucose transporters (Glut). Indeed, over-expression of glucose transporter genes 
has been reported in many kinds of tumors. 
Antisense oligonucleotides (ODNs) complementary to specific mRNA sequences 
are widely used as gene expression inhibitors by forming a hybrid duplex with the target 
nucleotide sequence. As the metabolic rate in most tumor cells is higher than that 
observed in normal cells, upset of the metabolism will affect tumor cells to a greater 
extent. Thus, treatment with antisense ODNs against Glut on tumor cells provides 
another approach for cancer therapy. However, application of antisense 
oligonucleotides is limited by the low efficiency of cellular uptake and their short half-
life. Thus, lipofectin, a cationic lipid, was used as a carrier to enhance the uptake of 
ODNs while the bases of ODNs were phosphorothioated in order to increase their 
stability. 
In this study, two cell lines, HepG2 and its multi-drug resistant R-HepG2 cells，were 
used to investigate the anti-tumor effect of antisense ODNs against Glut 2 at different 
ii 
time points (24 hr, 48 hr and 72 hr post incubation after transfection). Thus, antisense 
ODNs against Glut 2 were designed while sense ODNs were used for control. 
For in vitro studies, flow cytometry was used to determine the uptake of FITC-
labeled phosphorothioated antisense ODNs into cells in the presence of lipofectin while 
cell viability was examined by MTT assay. Conditions for antisense treatment on both 
cells were set to be 4 |iM ODNs and transfected for 15 hours. It was found that 
expression of Glut 2 in protein level after antisense treatment was reduced as revealed by 
Western Blot analysis. In the present study, ^H-2-deoxy-glucose uptake assay was used 
to measure the uptake of glucose in cells. Besides, ^H-thymidine incorporation assay 
and cell cycle analysis were used to investigate the effect of antisense on cell 
proliferation while annexin-V-FITC and PI assay was used to determine whether 
antisense treatment would lead to cell death. It was found that uptake of glucose in 
antisense treated cells was significantly lower and cellular ATP content was lower after 
antisense treatment. Antisense oligonucleotides against Glut 2 exerted antiproliferative 
effect on both cell lines by changing the cell cycle pattern. However, cells treated with 
antisense ODNs did not induce apoptosis. 
For in vivo studies, HepG2 and R-HepG2 cells, were inoculated into nude mice to 
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Study the effect of antisense in animal model. Tumor bearing nude mice were then 
administered subcutaneously with the antisense drug at a dosage of 5mg/kg/injection for 
successive five days. Tumor weight was significantly suppressed when compared with 
that of the sense and saline controls. Besides, no side effects of antisense treatment on 
the hosts' tissues such as heart and liver were observed as evidenced by the findings that 
the plasma levels of lactate dehydrogenase, creatine kinase, aspartate transaminase and 
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脫氧葡萄糖滲入法(3H-2-deoxy-glucose uptake assay) ’我們發現經反義寡核昔酸 
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Chapter 1 Introduction 
1.1 The facilitative glucose transporter family 
Glucose is the basic source of energy for mammalian cells and cellular glucose 
uptake is mediated by glucose transporter proteins. There are two types of glucose 
transporter systems responsible for transporting glucose. They are sodium-
dependent glucose co-transporters and facilitative glucose transporters. Na+-
dependent glucose co-transporters are active transporters for which energy in the form 
of ATP must be supplied. For the facilitative glucose transporters, they are 
responsible for transporting glucose down the concentration gradient and are different 
from Na+-dependent glucose transporters in that no ATP is required. In this project, 
only facilitative glucose transporters will be discussed as only this family is known to 
be involved in cancer development. 
The energy independent facilitative glucose transporter family (Glut) belongs to 
a large superfamily of 12 transmembrane segment transporters (Mueckler et al., 1994). 
Figure 1.1 shows the general structure of glucose transporter in which both the N and 
C termini are orientated at the cytoplasm. Transmembrane segments contain many 
amino acid residues having hydroxyl (OH) and carbonyl amino (CONH�) groups that 
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can interact with hydroxyl groups on glucose by forming hydrogen bonding. In this 
family, six structurally related proteins were isolated and characterized. The proteins 
are named Glut 1-5 and Glut 7 while Glut 6 is a pseudogene which does not express at 
the protein level. 
The facilitative glucose transporters exhibit tissue- and cell-specific distribution 
and a single cell type may express two or more isoforms. Glut 1 is present at various 
levels in human tissue so as to provide many cells with their basal glucose 
requirement. Glut 2 is expressed in hepatocytes, pancreatic jB cells, and the 
basolateral membrane of intestinal and renal epithelial cells. Glut 3 is responsible 
for glucose uptake into neurons. Glut 4 is expressed exclusively in the insulin-
sensitive tissues, namely fat and muscle. It is responsible for increased glucose 
disposal in these tissues in the postprandial state and is important in whole-body 
glucose homeostasis. Glut 5 is primarily a fructose transporter that is abundant in 
spermatozoa and the apical membrane of intestinal cells. Glut 7 is the transporter 
present in the endoplasmic reticulum membrane that allows the flux of free glucose 
out of the lumen of this organelle after the action of glucose-6-phosphatase on 
glucose-6-phosphate. 
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Figure 1.1 Predicted topology of Glutl. The 12 predicted transmembrane helices 
are numbered 1-12. The single N-linked oligosaccharide is designated by CHO. 
This is the general structure of glucose transporters (adapted from Mueckler et al, 
1994). 
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1.2 Overexpression of glucose transporters in tumor cells 
It has long been recognized that malignant cells depend mainly on glucose for 
energy supply and for growth. Thus, cancer cells show increased glucose uptake and 
utilization when compared with their non-malignant counterparts (Holroyde et al., 
1981). This may be due to their high proliferation rate (Grover et al., 1998). 
Increased glucose uptake can be achieved by expressing more glucose transporter 
genes. Thus, glucose transporter genes are overexpressed in many human cancer 
cells in order to provide extra energy for the rapid growth of cancer cells. 
Overexpression of Glut 1 and Glut 3 genes have been observed in tissues of 
human lung cancer (Ogawa et al., 1997), hepatoma (Yamamoto et al., 1990, Su et al., 
1990), brain tumor (Nishioka et al.’ 1992, Nagamatsu et al., 1993，Boado et al” 1994), 
islet cell tumor (Seino et al., 1993), head-and-neck tumor (Mellanen et al., 1994) and 
tumors of digestive system (Yamamoto et al., 1990) including gastric tumor, colon 
tumor, pancreatic tumor and esophageal tumor. Besides, overexpression of the Glut 
1 gene is also detected in human breast tumor (Brown et al., 1993) and human renal 
cell tumor (Nagase et al., 1995). Overexpression of Glut 2 is observed in liver 
cancer (Yamamoto et al., 1990). High level of Glut 5 was found in breast tumor 
tissue but not in normal breast tissue (Zamora et al., 1996). Furthermore, Glut 5 was 
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also found in human colon tumor cells (Mesonero et al, 1995). 
The increase of uptake rate of glucose during tumor development has been 
confirmed in experimental models. In studies using mice with Ehrlich ascites tumor 
(EAT) cells, it was found that during tumor development, the glucose uptake rate 
increased in parallel with increases in density of glucose transporters on the 
membrane (Chan et al., 1983)，using cytochalasin B binding as indicator for the 
presence of transporter molecules. Besides, it was found that the mRNA levels of 
Glut 1 and Glut 3 increase progressively in the tumor cells during tumor development 
in EAT cells bearing mice. However, there are no changes observed in the mRNA 
level of Gluts of all types in brain，liver and heart of the mice models (Au et al., 1997). 
These findings suggest that tumor may increase its glucose uptake when compared to 
other tissues in the host in response to its unique growth needs. Thus, it is 
conceivable that suppression of glucose transporter system in tumor cells should 
result in tumor regression. 
The phenomenon of increasing uptake rate of glucose in tumors has been used to 
develop positron emission tomography (PET) in oncological indications by 
administering fluorine-18-fluorodeoxyglucose, a glucose analogue, to the patients to 
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localize tumors in patients. Besides PET imaging can be used at different stages of 
diagnosis and follow-up to assess tumor metabolism and response to therapy (Rigo et 
aL, 1996, Delbeke et al., 1999，Hustinx et al., 1999, Shulkin et aL, 1999). 
Previous studies showed that the antimetabolite 2-deoxy-D-glucose which 
downregulated Glut 1 and inhibited glycolysis was toxic to cancer cell lines (Bentley 
et al, 1996). It was also found that glucose deprivation could induce cytotoxicity in 
breast carcinoma cells (Lee et al., 1998). Furthermore, it was found that antisense 
against Glut 1 could suppress glucose transporter expression level in gastric cancer 
cell line (MKN45) in an experiment in which the cells were transfected with antisense 
oligonucleotides against Glut 1 and subsequently, resulted in inhibiting tumor growth 
(Noguchi et al., 2000). These results indicated that alteration in glucose transport 
and glucose utilization would be adverse to cancer cells. In this project, we will 
examine the possibility of developing a new therapeutic mode in cancer management 
by suppressing the facilitative glucose transporter system of the cancer cells. 
Antisense nucleic acids against glucose transporter type 2 were used to down-regulate 
the expression of glucose transporter gene in HepG2 and a multi-drug resistant 
HepG2 cell line, namely R-HepG2 cells. 
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13 Antisense strategy 
The idea of using oligonucleotides with sequences complementary to specific 
mRNA to inhibit gene expression was first proposed by Zamecnik in 1978 (Zamecnik 
et al., 1978). Now, antisense oligonucleotides are commonly used as research tools 
to modulate gene expression through effects on gene stability, transcription, message 
processing, message stability or translation and thus preventing the expression of 
genes in protein level (Helene et al, 1990, Stein et al., 1993, Wagner et al., 1994， 
Crooke et al., 1996). The nucleotide sequence of DNA or RNA that contains the 
information for the amino acid sequence of the protein is called the sense strand while 
the sequence complementary to the sense strand is called the antisense strand. Thus, 
synthetic antisense oligonucleotides can be made to block individual gene expression 
if the sequence of the target gene is known. Antisense oligonucleotides are 
negatively charged single stranded DNA of about 15 to 20 nucleic acid bases long. 
This length provides sufficient binding affinity, selectivity and specificity towards the 
complementary target mRNA. Besides, short pieces of oligonucleotides are 
synthetically manufactured and chemically modified DNA or RNA can be made. 
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1.3.1 Modifications of oligonucleotides 
The half-life of oligonucleotides is short due to the activity of nucleases in tissue 
culture media and inside the cells (Thierry et al., 1992). Thus, chemical 
modification of the oligonucleotides is necessary to reduce their degradation and 
increase their stability. There are several chemical modifications for 
oligonucleotides. 
Phosphorothioated oligonucleotides 
The most commonly used and commercially available modified oligonucleotides 
are phosphorothioated (P=S) oligodeoxynucleotides. In this modification, the non-
bridging oxygen atoms in the phosphate backbone are replaced by sulfur atoms 
(figure 1.2), thereby forming a phosphorothioate linkage and provided a dramatic 
improvement in the antisense half-life in vitro and in vivo (Crooke et al., 1995). 
This modification has about 100- to 300-fold increase in nuclease resistance 
compared with a phosphodiester oligonucleotide (Cummins et al., 1995). Besides, 
phosphorothioated oligonucleotides retain a net charge and are soluble in water. In 
this project, this kind of modification was employed. 
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Figure 1.2 Modification of oligonucleotides. Phosphorothioation is one of the 
modification methods in which the oxygen atom in the backbone is replaced by a 
sulphur atom. 
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Modifying sugar moiety 
Modifying the C’ position of the sugar (ribose) of oligonucleotides can increase 
the nuclease resistance of oligonucleotides. Modifications to this position include 
2'-fluororibonucleotides (Kawasaki et aL, 1993), 2‘-propoxyribonucleotides (2,-0-
propyl) (McKay et al., 1996) and 2'-0-methoxyethylribonucleotides (2'-M0E) 
(McKay et al., 1999). However, modifications of the oliognucleotides at the 2’ 
position of the sugar do not support the cleavage by RNase H. In order to overcome 
this problem, gapmers or chimeric oligonucleotides have been designed (McKay et al., 
1996, Monia et al., 1993). These oligonucleotides contain both C2'-modified bases 
(to increase nuclease resistance and hybridizing affinity) combined with a series of 
consecutive gaps of oligonucleotide residues (at least 6 or 7 unmodified, consecutive 
oligonucleotide residues) for the recognition and cleavage by RNase H (Monia et al” 
1993, Monia et al., 1996, Agrawal et al., 1997). 
Backbone substitutions 
Another modification method is to replace the entire ribose-phosphate backbone 
by a peptide backbone to form peptide nucleic acid (Hyrup et al., 1996 and Sanghvi et 
a/., 1997). Pentose nucleic acid and phosphonester nucleic acid are two examples 
(figure 1.3). 
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Figure 1.3 Modification of oligonucleotides. Replacement of ribose phosphate 
backbone by peptide backone can increase the nuclease resistance of oligonucleotides. 
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1.3.2 Delivery system for oligonucleotides 
Another major problem in the use of antisense oligonucleotides is the ability to 
deliver these oligonucleotides into cells so as to reach their target. Besides, native 
phosphodiester oligonucleotides and widely used phosphorothioate modified 
oligonucleotides are polyanions. Thus, they have little or even no ability to diffuse 
across cell membranes. In tissue culture, antisense oligonucleotide activity can be 
greatly improved by the use of a delivery system to enhance cellular uptake of 
oligonucleotides (Gewirtz et al” 1996). Liposomes are the most commonly used 
delivery system for oligonucleotides. Liposomes are of potential interest because 
they are made of phospholipids, which are natural constituents of all the cell 
membranes. Although the exact mechanism that the liposomes help in delivery of 
oligonucleotides is not known, a mechanism has been proposed recently by Zelphati 
et al. (1996) that DNA/liposome complexes are taken up by cells by an endocytosis 
mechanism (figure 1.4). The complex probably induces a flip-flop of anionic 
phospholipids in the endosome membrane, leading to neutralization of the cationic 
lipid charge, displacement of the bound oligonucleotide and finally release from the 
endosome. Besides, studies showed that after addition to cells, the liposomes 
initially co-localized with the oligonucleotides on the cell surface and in fine punctate 
structures within the cytoplasm. At later times, the oligonucleotide began to 
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accumulate in the nucleus as well as the cytoplasm. On the other hand, the 
liposomes remained localized to the cell surface and the cytoplasm and was absent in 
the nucleus (Marcusson et al, 1998). In this study, cationic liposomes were used 
which are composed of cationic lipid N-[l-(2，3-dioleyloxy)propyl]-n，n,n-
trimethylammonium chloride (DOTMA), and neutral helper lipid dioleoyl 
phosphotidylethanolamine (DOPE). 
On the other hand, the cellular uptake processes in animals are different from 
that in tissue culture. In animal, antisense effects can be seen without using delivery 
systems (Dean et al., 1994). It was found that phosphorothioated antisense 
oligonucleotides injected into animals would distribute quickly to different organs 
with the greatest amount in liver and kidney (Agrawal et al., 1991, Cossum et al., 
1993, Sands et al., 1994，Rifai et al, 1996, Geary et al., 1997). 
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Figure 1.4 Key steps in the delivery of gene drugs to target cells through 
endocytosis. (1) Packaging of DNA into a deliverable particle. (2) Delivery of 
nucleic acid drugs to the target cells. (3) Association of the delivery system with 
target cell membranes by non-specific binding or site specific, cell surface ligand, 
followed by either direct fusion with the plasma membrane or receptor mediated 
endocytosis and subsequent endosome disruption. (4) Diffusion of DNA through the 
cytoplasm and nuclear membrane pores. (5) Gene transcription and the production of 
therapeutic protein, or (6) inhibition of mRNA translation into protein by antisense 
oligonucleotides and ribozymes (adapted from Hope et al., 1998). 
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1.3.3 Factors influencing antisense activity 
Affinity 
The affinity of oligonucleotides for their targeted sequences results from 
hybridization interactions. Hydrogen bonding and base stacking in the double helix 
formed are the two major sources of energy for binding of oligonucleotides to targeted 
sequences. Moreover, affinity is affected by ionic strength: the higher the ionic 
strength, the higher the affinity of charged oligonucleotides for polynucleotides. As 
affinity results from hydrogen bond formation between bases and stacking occurs 
between coplanar bases, affinity increases as the length of the oligonucleotide 
complex increases. As a result, the affinity per nucleotide pair is crucial 
determinants of overall affinity (Breslauer et al ,1986, Freier et al ,1986, Crook et al., 
1999). 
Specificity for nucleic acid sequences 
Specificity derives from the selectivity of base pairing. The decrease in affinity 
associated with a mismatched base pair varies as a function of the specific mismatch, 
the position of the mismatch in a region of complementarity and the sequence 
surrounding the mismatch. Studies showed that it is necessary to manipulate the 
length of the oligonucleotide and its concentration at target in order to exploit fully 
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the theoretical potential for specificity of an oligonucleotide in a therapeutic context 
(Monia et al., 1992，Crooke et al., 1999). 
1.3.4 Mechanism of action of antisense oligonucleotides 
Initially, oligonucleotides are taken up by cells through endocytosis. Then, 
oligonucleotides are released from endosomes and enter the cytoplasm. Upon 
binding to the target mRNA insides the cells, there are several potential mechanisms 
by which antisense oligonucleotides can inhibit protein synthesis. 
Translational arrest 
The mechanism for which the majority of oligonucleotides have been designed is 
translational arrest by binding to the translation initiation codon. In this mechanism, 
antisense oligonucleotides first bind to the target mRNA using Watson-Crick base 
pairs to form DNA/RNA double helix. This can sterically block the movement of 
the ribosome along the targeted transcript or ribosomal assembly and subsequently, it 
can block the translation of the mRNA and prevent protein synthesis (figure 1.5). 
Interference with splicing of pre-mRNA 
Antisense oligonucleotides can prevent or modify RNA splicing. 
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Oligonucleotides that bind to sequences required for splicing may prevent the binding 
of necessary factors or physically prevent the required cleavage reactions. 
Subsequently, inhibition of the production of the mature mRNA would result (Crooke 
et al., 1999, Sierakowska et al., 2000). The ability to modulate splicing through the 
use of antisense oligonucleotides provides a novel and powerful tool to regulate gene 
expression. Instead of using antisense oligonucleotides to eliminate gene expression, 
this approach can also be used to select expression of an alternatively expressed 
transcript and hence, result in the expression of a desired protein product. 
RNase H mediated degradation of hybridized mRNA 
RNase H is an enzyme that degrades the RNA strand of the DNA/RNA hybrid 
duplex (Kanaya et aL, 1995) (figure 1.5). This family of endonucleases cleaves the 
RNA, producing 5'-phosphate and 3'-hydroxy termini. The resulting cleavage 
products lack a 5,-cap and 3’-polyadenylation and result in degradation of mRNA by 
5,- and 3'-exonucleases. Thus, the target RNA is degraded while the 
oligonucleotide is not cleaved by RNase H and can then hybrid to a new target mRNA 
transcript. As a result, one antisense oligodeoxynucleotide can mediate the RNase 
H-dependent cleavage of many target mRNA transcripts (Lima et aL, 1997, Cooper et 
a/.，1999). This mechanism is an effective catalytic means. Although the precise 
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recognition elements for RNase H are unknown, it has been shown that 
oligonucleotides with DNA-like properties as short as tetramers can activate RNase H 
(Keller et al., 1979) and phosphorothioates are excellent substrates (Cazenave et al, 
1989, Mirabelli et al., 1991). 
Triple helix formation 
Inactivation of gene expression by oligonucleotides might also be exerted by 
triple helix formation between genomic double-stranded DNA and oligonucleotides 
(figure 1.5). This sequence specific binding is achieved through hydrogen bonds 
between thymidine and TA base pairs and between protonated cytosine and CG base 
pairs (Mergny et al., 1992). Besides, a second motif for triplex formation is 
comprised by a homopurine motif in which a purine-rich oligonucleotides binds to 
DNA antiparallel to the Watson-Crick purine strand (Beal and Dervan, 1991). 
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Figure 1.5 Main mechanisms of the antisense strategy (adapted from Bochot et al., 
2000). 
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1.3.5 Clinical trials of antisense treatment 
Human studies of phosphorothioated oligonucleotides are being investigated in 
clinical trials (table 1.1). Among the twelve different clinical studies, some are 
involved in cancer development (c-myb, bcl-2, PKA, PKC-alpha, c-raf kinase and Ha-
ras) while some are involved in viral diseases and inflammatory diseases. 
For protein kinase C (PKC), it is overexpressed in a variety of cancers. 
Antisense oligonucleotides targeted against PKC-alpha can inhibit protein expression 
and the growth of tumors in vitro and in vivo. In Phase I study, the safety profile is 
characterized and the maximum tolerated dose of antisense to PKC-alpha when 
administered by continuous infusion in patients is determined (Yuen et al., 1999). It 
is now under Phase II study. 
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Target Indication Phase 
c-myc (LR-3280) Restenosis I 
c-myb (LR-3001) Leukemias I 
PKA (GEM 231) Solid tumors I 
Ha-ras (ISIS 2503) Solid tumors I 
bcl-2 (G3139) Solid tumors n 
PKC-alpha (ISIS 3521) Solid tumors H 
c-raf kinase (ISIS 5132) Solid tumors n 
Cytomegalovirus (ISIS 13312) CMV retinitis I 
Cytomegalovirus (GEM 132) CMV retinitis/systemic H 
Cytomegalovirus (ISIS 2292/fomivirsen) CMV retinitis 3 NDA 
filed 
HIV (GEM 92) HIV I 




Table 1.1 Antisense oligonucleotides in clinical trials (modified from Marcusson et 
al., 1999). 
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1.4 Objective of present project 
Since glucose is an essential nutritional requirement of tumor cells, suppression 
of its uptake might be an effective anti-cancer strategy. In order to test whether the 
glucose transport system can serve as an anti-tumor target, we used antisense 
oligonucleotides to suppress Glut gene expression in tumor cells. Besides, 
biochemical changes in tumor cells after antisense treatment were investigated. Glut 
2 has been selected as the target of antisense treatment in both HepG2 and R-HepG2 
cells. It is because although Glut 1，Glut 2 and Glut 3 are overexpressed in liver 
cancer cells (Yamamoto et al, 1990), Glut 2 is more liver-specific. 
The present project was divided into in vitro and in vivo experiments. In in 
vitn) studies, human hepatoma HepG2 cells and its multi-drug resistant cells (R-
HepG2) were used. In in vivo studies, HepG2 / R-HepG2 cells bearing nude mice 
were used to test the effect of antisense oligonucleotides against Glut 2. The 
cytotoxicity of this antisense was investigated by measuring the tumor size. Besides, 
probable side effects of antisense to other tissues such as liver and heart were also 
determined. 
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Chapter 2 Materials and Methods 
1.1 Materials 
2.1.1 Reagents and Buffers 
Preparation of buffers 
Buffer was prepared from dissolving chemicals in distilled water (dH20) and 
titrated to suitable pH with either hydrochloric acid (HCl) or sodium hydroxide 
(NaOH), unless otherwise specified. 
Phosphate buffered saline (PBS) was prepared by composing 136 mM 
sodium chloride NaCl, 2.7 mM potassium chloride KCl, 1.5 mM potassium hydrogen 
phosphate KH2PO4 and 8 mM sodium hydrogen phosphate Na2HP04. The pH of 
PBS was adjusted to 7.4 and was then sterilized by autoclaving. PBS was stored at 
room temperature. 
Normal saline ~ 0.9% (w/v) NaCl was prepared by dissolving 9g of sodium 
chloride powder into one litre of distilled water. It was stored at room temperature. 
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2.1.2 Reagents for Western blot analysis 
Lysis buffer for total protein extraction was prepared by preparing of 1 % (w/v) 
sodium dodecyl sulfate (SDS)，ImM sodium meta-vanadate (Nsl^YO^), 10 mM tris, 5 
mM magnesium chloride (MgCy，21 )Lig/ml aprotinin, 5 |Lig/ml leupeptin and 1 mM 
phenylmethyl-sulfonyl fluoride (PMSF). All these components were dissolved in 
PBS. Buffer was adjusted to pH 7.4 and stored at room temperature. 
Protein standard (2 mg/ml) was prepared by dissolving 0.02g bovine serum 
albumin (BSA) in 10 ml distilled water and stored at -20 
10% (w/v) ammonium persulfate (APS) was prepared by dissolving Ig 
ammonium persulfate powder in 10 ml distilled water. APS was then stored at -20 
4 X lower gel buffer was prepared by composing 1.5 M Tris-Cl and 14 mM 
sodium dodecyl sulfate (SDS). Buffer was adjusted to pH 8.8 and stored at room 
temperature. 
4 X upper gel buffer was prepared by composing 0.5 M Tris-Cl and 14 mM 
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sodium dodecyl sulfate (SDS). Buffer was adjusted to pH 6.8 and stored at room 
temperature. 
12 % separating gel buffer was prepared by mixing 3.2 ml acrylamide/bis-
acrylamide (30 %) solution, 2 ml 4 X lower gel buffer, 40 |il 10% ammonium 
persulfate (APS), 9.3 |LI1 N, N，N,, N'-tetramethyl-ethylene diamine (TEMED) and 
2.75 ml distilled water. Mixture should be prepared freshly for each experiment. 
4.5 % stacking gel buffer was prepared by mixing 0.6ml acrylamide/bis-
acrylamide (30 %) solution, 1 ml 4 X upper gel buffer, SOjul 10% ammonium 
persulfate (APS), 5.3 jal TEMED and 2.4 ml distilled water. Mixture should be 
prepared freshly for each experiment. 
2 X SDS loading buffer was prepared by dissolving 2 % (w/v) SDS, 10 % (w/v) 
sucrose, 0.002 % bromophenol blue and 62.5 mM Tris base in distilled water. 
Buffer was then adjusted to pH 6.8 by HCl. Finally, the loading buffer was 
supplemented with 5 % (v/v) 2-mercaptoethanol and stored at 4 � C . 
SDS running buffer was prepared by composing 25 mM Tris base, 192 mM 
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glycine and 0.1 % (w/v) SDS and stored at room temperature. 
Electroblot buffer was prepared by composing 25 mM Tris base, 192 mM 
glycine and 15 % (v/v) methanol in distilled water and stored at room temperature. 
TBS-Tween-20 (TBS-T) was prepared by composing 10 mM Tris base, 0.15 M 
NaCl and 0.1 % (v/v) Tween-20. TBS-T was stored at room temperature. 
Commassie Blue staining solution for staining protein was prepared by 
composing acetic acid, methanol and distilled water in the ratio of 1:3:10 and 
supplemented with 0.05 % (w/v) commassie brilliant blue R-250. The staining 
solution was stored at room temperature. 
De-stain solution for removing commassie brilliant blue R-250 was prepared 
by composing 40 % (v/v) methanol and 10 % (v/v) acetic acid. The de-stain solution 
was stored at room temperature. 
2.1.3 Culture Medium 
Roswell Park Memorial Institute tissue culture medium 1640 (RPMI 1640 
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medium) was used for cell culture. Each pack of the powder of RPMI 1640 medium 
with phenol red, L-glutamine and 0.5 mM HEPES buffer was dissolved in 1 liter of 
dHsO. The medium was supplemented with 2 g NaHCO�. The pH of the medium 
was adjusted to 7.4. Finally, medium was sterilized by filtration using a membrane 
with a porosity of 0.22 |am bottle-top filter (Millipore). The complete RPMI 1640 
medium was supplemented with 1 % penicillin-streptomycin (v/v) and 10 % fetal 
bovine serum (FBS) (v/v). Culture medium was stored at 4 All RPMI 1640 
powder, fetal bovine serum and penicillin-streptomycin (10,000 U/ml) were brought 
from Gibco BRL Life Technology. 
2.1.4 Chemicals 
Dye for cytotoxicity assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), was purchased from Sigma. Five mg/ml MTT 
solution was prepared by dissolving MTT powder in PBS. The solution was then 
filtered through filter paper (Whatman) to remove any undissolved crystals. Finally, 
MTT solution was stored at 4 � C . 
Doxorubicin was purchased from Sigma. It was dissolved in autoclaved 
distilled water to give the stock concentration of 5mg/ml. PBS was then used to 
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dilute the stock solution to lOOjiM or 500|iM for use in cell culture. The 
doxorubicin solution was stored at 4 � C . 
2-Deoxy-D-[l-'H] glucose (1.0 mCi/ml) and [methyl-'H] thymidine were 
purchased from Amersham. 
Lipofectin Reagent was purchased from Life Technologies (GIBCO BRL). 
Lipofectin Reagent is a 1:1 (w/w) liposome formulation of the cationic lipid N-[l-
(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA), and dioleoyl 
phosphotidylethanolamine (DOPE). This liposome can interact with DNA to form a 
lipid-DNA complex and help mediate the transport of DNA into the cells. The 
concentration of Lipofectin Reagent was 1 mg/ml and the solution was stored at 4 � C . 
Antisense and sense phosphorothioate oligodeoxynucleotides (ODN) 
molecules, 15 base pairs, against glucose transporter 2 were designed. The ODNs 
used in both in vitro and in vivo studies in this project were synthesized by Golden 
Pacific Ltd. (Hong Kong). The oligonucleotide was purified by C18 cartridge. The 
ODN was phosphorothioated at each base and the commercial oligodeoxynucleotides 
were reconstituted in sterile PBS. The solution was then made sterile with a 0.22 jtim 
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filter and it was stored at -20 
Fluorescein-5-isothiocyanate (FITC) labeled phosphorothioate 
oligodeoxynucleotides (ODN), 15 base pairs, were synthesized by Golden Pacific 
Ltd. (Hong Kong). Fluorescein was covalently bound to ODNs at 5' end. The 
oligonucloetide was purified by PAGE. The labeled ODN was phosphorothioated at 
each base and the commercial oligodeoxynucleotides were reconstituted in sterile 
phosphate buffered saline (PBS). The solution was then made sterile with an acetate 
0.22 |Lim filter and stored at -20 covering with foil. 
2.1.5 Culture of Cells 
2.1.5.1 Differentiated Human Hepatoblastoma cell line (HepG2) 
HepG2 cell line was purchased from American Type Culture Collection (ATCC, 
Rockville, MD, USA). It was derived from a liver tumor biopsy obtained during 
extended lobectomy of a 15-year-old Caucasian male from Argentina (Aden et al., 
1979). The liver tumor was diagnosed histologically as a well-differentiated 
hepatoblastoma. HepG2 were adhesive cells and were maintained as monolayer 
culture in RPMI 1640 medium (GIBCO BRL) supplemented with 10% FBS and 1% 
penicillin-streptomycin (complete medium). HepG2 cells were grown at 37�C, 5% 
Chapter 2 Materials and Methods Page 32 
CO2 incubator with humidified atmosphere. Cells were cultured in 150 cm^ culture 
flask (Coming) and were subcultured approximately once every three or four days. 
In every passage, medium was discarded and cells were washed once with PBS. 
Then cells were trypsinized with 2ml trypsin-EDTA (0.25% trypsin, ImM EDTA) 
(GIBCO-BRL) by incubating at 3 7 � C for 3 minutes. Complete medium was added 
to stop trypsinization. The cell suspension was centrifiiged at lOOOx g for 3 minutes. 
Complete medium was then used to resuspend the cell pellet. Cells were seeded at a 
density of 5x 10^  cells in 25ml comlpete medium per flask. 
2.1.5.2 Multi-drug resistant hepatoma cell line, R-HepG2 cells 
Multi-drug resistant cell line (R-HepG2) was developed in our laboratory by 
incubating HepG2 cells in stepwise increased concentrations of doxorubicin (Sigma), 
starting from 0.1 |LIM and ending up to 100 |LIM. When HepG2 cells were grown to 
about 80% confluence, they were treated with doxorubicin at concentration 0.1 juM 
which caused 90% cell death with 48 hours incubation. After 24 hours incubation 
with doxorubicin, cells were washed several times with PBS. Cells were then 
incubated in fresh medium for another 24 hours. After that, the cells were washed 
several times with PBS again and incubated with fresh medium. This washing 
procedure was repeated until the cells grew to confluence. Cells were trypsinized 
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and divided into two new flasks. After the cells has grown to 80% confluence, 
0.2 |LIM doxorubicin was incubated with the cells. The treatments were repeated 
until the cells grew at 100 |LIM doxorubicin. Through these processes, the resistant 
cells were selected by removing the dead non-resistant cells. Finally, the multi-drug 
resistant HepG2 cells (R-HepG2) were maintained by culturing the cells at 1.2 |aM 
doxorubicin. 
2.1.6 Animal Studies 
Inbred male Balb/c and nu/nu nude mice aged 6-8 weeks were bred at the 
Laboratory Animal Services Center of The Chinese University of Hong Kong under 
pathogen-free condition. Nude mice were fed with autoclaved tape water ad libitum 
with animal diet (PICO LAB® Rodent Diet). The mice were kept in autoclaved 
filter-top cages at the Laboratory Animal Services Center of The Chinese University 
of Hong Kong under pathogen-free condition during experiment. The polyester fiber 
filters were used to avoid contact of the mice with pathogens. The animal protocol 
was approved by the Animal Research Ethics Committee, The Chinese University of 
Hong Kong. 
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2.2 Methods 
2.2.1 In vitro studies 
2.2.1.1 Design of oligonucleotide sequence 
The full sequence of human glucose transporter 2 was obtained from sequence 
database of GenBank in NCBI homepage (http://www.ncbi.nlm.nih.gov/entrez). 
Then, the sequence of antisense Glut 2 was selected to be complementary to the 
human Glut 2 cDNA sequence within the coding region. The length of 15 base pairs 
antisense sequence was chosen within the coding region starting from base 1393 to 
base 1407. The antisense sequence was: 5'- ACG TCG CCC TGC CTT -3 ' . The 
sequence of sense control for Glut 2 was the same as the sequence of the human 
glucose transporter 2 cDNA sequence from the base 1393 to base 1407. The sense 
sequence was: 5'- AAG GCA GGG CGA CGT -3,. The specificity of the 
sequence selected was checked by using the program 'Blast search' in GenBank. 
There should be no appreciable overlapping with other human cDNA sequences. 
Otherwise, another sequence should be selected. 
All the ODNs were phosphorothioated at each base. Thus, a sulfur atom 
replaced one of the non-bridging oxygen atoms in the phosphodiester bond. This 
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modification could enhance the stability of ODNs. 
2.2.1.2 Transfection 
Cells in complete RPMI 1640 medium were seeded on plates and incubated at 
37 5 % CO2 with humidified atmosphere overnight to allow the cells adhere to the 
plates. 
On next day, transfection was carried out in which a carrier, lipofectin reagent 
(GIBCO-BRL), was used to enhance the uptake of oligonucleotides into cells. 
Firstly, lipofectin reagent and oligonucleotides were each diluted separately into 
RPMI 1640 medium without serum and antibiotics, namely serum free medium, and 
incubated for 45 minutes at room temperature. After that, the diluted 
oligonucleotides were mixed with the diluted lipofectin reagent (cationic lipid) and 
further incubated for 15 minutes at room temperature for the formation of cationic 
lipid-oligonucleotide complex. Then, the medium in the plate was discarded and the 
cells were washed twice with serum free medium. Finally, the cationic lipid-
oligonucleotide complex solution (in serum free medium) was added to the cells and 
incubated at 3 7 � C , 5 % CO� with humidified atmosphere for 15 hours. After 15 
hours transfection, the complex solution was removed from the cells. Then, the cells 
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were washed twice with serum free medium. Finally, fresh complete RPMI 1640 
medium was added to the cells and further incubated at 37 5 % CO2 with 
humidified atmosphere for 24 hours or 48 hours or 72 hours. Assays were then 
performed after 24 hours post-incubation, 48 hours post-incubation and 72 hours post-
incubation. 
2.2.1.3 MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
assay 
The viability of cells can be determined by MTT assay. HepG2 cells at Ix 
or R-HepG2 cells at 2x 10^ were seeded on 96-well plate (flat bottom) per well in 100 
III complete medium and incubated at 37�C，5 % CO2 with humidified atmosphere 
overnight. Then, transfection was carried out. After 24 hrs, 48 hrs and 72 hrs post 
incubation, MTT assay was carried out. The medium was removed and the cells 
were washed with PBS once. Then, 50 |LI1 MTT solution (5 mg/ml) was added into 
each well and the plate was incubated at 3 7 � C , 5 % CO� with humidified atmosphere 
for 2 hours. After that, the MTT solution was discarded and 100 jul/well DMSO 
(dimethyl sulfoxide) was added and incubated at 37 for 15 minutes until the purple 
crystals dissolved completely. Besides, blanks were set by adding 100 j^ l DMSO 
only. Then, the plate was shaken for a while and the optical density was measured at 
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wavelength 540nm by an ELISA microplate reader (BIO-RAD). 
Statistical calculations 
For each test, five repeats were used. Percentage cell survival was expressed as 
mean 土 standard deviation (S.D.). The percentage of cell survival was defined as 
follows: 
Percentage of cell survival = [(Mean OD of experiment / Mean OD of control)] x 100% 
where control cells were incubated with complete medium only. 
2.2.1.4 Flow cytometry 
Introduction 
Flow cytometry (FCM) has been used extensively to analyze various biological 
properties of cells (Ormerod, 1994). FCM is the measurement of cells in a flow 
system that has been designed to deliver particles in single file past a point of 
measurement. A basic flow cytometer consists of a source of light such as laser 
beam, a flow cell, optical components to focus light of different colors on to the 
detectors, electronics to amplify and process the resulting signals and a computer 
(figure 2.1). The flow cell is to deliver cells singly to a specific point by 
hydrodynamic focusing at which the source of light is focused. This is achieved by 
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injection of the sample into the center of a stream of liquid called the sheath fluid. 
Light source strikes on the cells and the emission of light is collected by detectors. 
Image analysis by computer was then made to study the distribution of light signals 
emitting from a population of cells. 
Procedure for detecting cellular accumulation of FITC-labeled oligonucleotide or 
doxorubicin by flow cytometry 
5x 105 HepG2 cells or 6x 10^  R-HepG2 cells in 2 ml complete medium were 
seeded on 6-well plate per well and incubated at 3 7 � C , 5 % CO� overnight. Then, 
transfection was carried out in which FITC-labeled oligonucleotide was used. After 
different transfection time (8 hr, 12 hr, 15 hr, 18 hr and 24 hr), cells were washed by 
PBS and then trypsinized. Then, the cells were washed with PBS twice. Finally, 
PBS was used to resuspend the cell pellet and the cells were analyzed using 'Lysis 11, 
program in flow cytometer. Green fluorescence was monitored with 530/30nm 
bandpass filter and photomultiplier tube pulses were amplified logarithmically. Ten 
thousand cells were counted. The population of live cells was determined by 
forward scatter (FSC) light and side scatter (SSC) light while the signals from dead 
cells were rejected. FSC and SSC determined the size and the granularity of a cell 
respectively. Finally, the signal of FITC was collected at channel FL-1 (green 
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fluorescence). The mean fluorescence intensity of the population of FITC-labeled 
oligonucleotide treated cells was calculated using histograms and was expressed in 
arbitrary units. 
For measuring doxorubicin uptake, 5x 10^  HepG2 cells or 6x 10^  R-HepG2 cells 
in 2 ml complete medium were seeded on 6-well plate per well and incubated at 37 
5 % CO2 overnight. Then, doxorubicin was added to the cells and incubated for 24 
hours at 37�C，5 % CO2. Then, similar procedure was carried out as described 
above except 630nm longpass filter was used instead because doxorubicin emitted red 
fluorescent signal which was collected at channel FL-2 (linear scale). 
Procedure for detection of cell cycle by flow cytometry 
5x 10' HepG2 cells or 6x 10' R-HepG2 cells in 2 ml complete medium were 
seeded on 6-well plate per well and incubated at 37。(：，5 % CO� overnight. Then, 
transfection was performed. After 24 hrs, 48 hrs or 72 hrs post-incubation, the cells 
were used for cell cycle analysis. Both floating cells and adherent cells were 
collected. Adherent cells were collected after trypsinization. Cells were then 
washed with PBS. Finally, cells were resuspended in ice-cold 70% ethanol and 
stored at 4 � C overnight. After that, cells were resuspended in 800 jil PBS, 100 jiil 
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RNase A (1 mg/ml) and 20 |LI1 PI (2 mg/ml). The mixture was then incubated at 37 
for 30 min. Cells were analyzed by using flow cytometry and channel FL-2A 
(linear scale) was selected. 
Procedure for detection of apoptotic and necrotic cells by annexin-V-FITC and PI 
assay using flow cytometry 
Phosphatidylserine (PS), which is one of the components of the plasma 
membrane, locates on the intracellular phase in normal living cells. However, in 
apoptotic cells, PS is translocated within the plasma membrane so that it appears on 
both the inner and outer surface. This surface appearance of PS was achieved by 
using energy provided by ATP. Thus, specific binding of annexin-V-FITC to PS can 
be used to locate PS in apoptotic cells. PI is used for the detection of necrotic cells. 
In normal living cells, PI cannot diffuse into cells due to the membrane integrity. 
However, in necrotic cells, PI can diffuse into the cytoplasm, bind to DNA and emit 
fluorescence as the membrane integrity cannot be maintained in necrotic cells. 
Moreover, annexin-V can diffuse into necrotic cells and bind with the intracellular PS 
as a result of the loss of membrane integrity. Thus, both annexin-V and PI emit 
fluorescence in necrotic cells. On the other hand, since membrane integrity is still 
maintained in apoptotic cells, PI cannot diffuse into apoptotic cells. 
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Data in a dot plot can be divided into four quadrants. The x-axis represents the 
green fluorescence intensity of annexin-V-FITC while the y-axis represents the red 
fluorescence intensity of PL Only few cells are detected in the upper left quadrant 
(annexin-V-FITC —ve，PI +ve). Viable cells can be found in the lower left quadrant 
(annexin-V-FITC -ve, PI -ve). Lower right quadrant represents apoptotic cells 
(annexin-V-FITC +ve, PI 一ve) while necrotic cells are found in the upper right 
quadrant (annexin-V-FITC +ve, PI +ve). Addition of digitonin (1 mg/ml) 
permeabilized the cells and this was used as a positive control (figure 2.2). Cells 
occurred in the upper right quadrant after treating the cells with digitonin as both PI 
and annexin-V-FITC could enter the cells and emit fluorescence due to the loss of 
membrane integrity. 
5x 105 HepG2 cells or 6x 10^  R-HepG2 cells in 2 ml complete medium were 
seeded on 6-well plate per well and incubated at 37 5 % CO2 overnight. Then, 
transfection was performed. After 24 hrs, 48 hrs or 72 hrs post-incubation, the cells 
were used for annexin-V-FITC and PI assay. Both floating and adherent cells were 
collected. Adherent cells were collected after trypsinization. Then, the steps 
should be done in dark environment. Half million cells were loaded with 100 
incubation buffer containing 2% (v/v) annexin-V-FITC and incubated for 20 min at 
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room temperature. Cells were then loaded with 400 jul incubation buffer containing 
2.5 jLig/ml PI and incubated at room temperature for further 20 min. Flow cytometric 
method was then used and signals of annexin-V-FITC and PI were collected at 
channels of FL-1 (green fluorescence) and FL-3 (red fluorescence) respectively. FL-
1 and FL-3 were set at logarithm (log) scale. 
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Principle of flow cytometry (Becton Dickinson, FacSort model). 
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Figure 2.2 Analysis of mode of cell death by the use of annexin-V-FITC and PI 
assay. 
5x 105 HepG2 cells or 6x 10^  R-HepG2 cells in 2 ml complete medium were seeded 
on 6-well plate per well and incubated at 37�C, 5 % CO2 overnight. Then cells were 
used for annexin-V-FITC and PI assay. For the positive control, cells were treated 
with 1 mg/ml digitonin to permeabilize plasma membrane. Dot plots were divided 
into four quadrants. The percentage of cells in each quadrant was calculated. 
Almost all of the cells were shifted to the upper right quadrant in the positive control 
group and this mimicked most of the cells are the necrotic cells with the addition of 
digitonin. 
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2.2.1.5 ^H-thymidine incorporation assay 
5x 104 HepG2 cells or 6x 10^  R-HepG2 cells in 0.5ml complete medium were 
seeded on 24-well plate per well. Plates were incubated at 3 7 � C , 5 % CO� incubator 
overnight. Then, transfection was performed. After 24 hrs, 48 hrs or 72 hrs post-
incubation, ^H-thymidine incorporation assay was carried out. First, medium was 
discarded and cells were washed with PBS twice. Then 1 jnCi [methyl-^H] 
thymidine (Amersham) in 0.5ml complete medium was added to each well and 
incubated at 37 °C，5 % CO? for 3 hours. Then, the medium was removed and the 
cells were washed with PBS twice. Volume of 0.5ml 12% trichloroacetic acid (TCA) 
was then added and the plate was stood at room temperature for 1 hour. After that, 
the TCA was discarded and the cells were washed with PBS twice. Finally, 200 jul 
of 0.1% sodium dodecyl sulfate (SDS) and 50 of IM NaOH were added to each 
well to lyse the cells. Then, 150 i^l lysate was then mixed with 1.5ml scintillation 
cocktail in scintillation vial for counting by using Beckman LS7000 liquid 
scintillation counter. Volume of 5 jiil of the cell lysate was used to perform 
bicinchoninic acid assay (BCA) (referred to section 2.2.1.8 Western blotting for 
protein determination) in order to determine the protein amount and samples were 
tested in triplicate in this assay. 
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Statistical calculations 
^H-thymidine uptake was calculated as follows: 
^H-thymidine uptake (counting / jig protein)= 
Radioactivity (count per minute) 
Protein concentration of 150 |LI1 0.1 % SDS solution 
2.2.1.6 2-Deoxy-D-[l-^H] glucose uptake assay 
5x 104 HepG2 cells or 6x 10^  R-HepG2 cells in 0.5ml complete medium were 
seeded on 24-well plate per well. Plates were incubated at 37 5 % CO2 incubator 
overnight. Then, oligo/lipofectin complex was added to each well for 15 hours at 
3 7 � C . Serum-free medium was then replaced by fresh complete medium after 
transfection. After 24 hrs, 48 hrs or 72 hrs post-incubation, 2-Deoxy-D-[l-^H] 
glucose uptake assay was performed. First, medium was discarded and the cells 
were washed with PBS twice. Then, 0.ImM 2-deoxy-D-glucose and 1 juCi 2-deoxy-
D-[1-3H] glucose (Amersham) in 0.5ml PBS was added to each well and incubated at 
3 7 � C for 15 minutes. The reaction was terminated by removing the tritium-labeled 
reaction mixture. The cells were then washed with lOmM 2-deoxy-D-glucose 
dissolved in PBS twice. After that, 200 |LI1 0.1% sodium dodecyl sulfate (SDS) was 
added to lyse the cells. Finally, 150 |LI1 of the lysate was transferred to scintillation 
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vials and mixed with 1.5ml scintillation cocktail. The vials were then used for 
radioactivity measurement (Beckman LS7000 liquid scintillation counter). For the 
remaining lysate, volume of 10 |LI1 of the cell lysate was used to perform bicinchoninic 
acid assay (BCA) (referred to section 2.2.1.8 Western blotting for protein 
determination) in order to determine the protein amount and samples were tested in 
triplicate. 
Statistical calculations 
2-Deoxy-D-[l-^H] glucose uptake was calculated as follows: 
2-Deoxy-D-[l-^H] glucose uptake (counting / fig protein)= 
Radioactivity (count per minute) 
Protein concentration of 150 jiil 0.1% SDS solution 
2.2.1.7 Adenosine-S'-triphosphate (ATP) assay 
Principle of the Adenosine-5 '-triphosphate (ATP) assay 
In this assay, the enzyme, phosphoglycerate phosphokinase (PGK), was used to 
catalyze the following reaction: 
ATP + 3-Phosphoglycerate ^ ^ • ADP + 1,3-Diphosphoglycerate 
Besides, the enzyme, glyceraldehyde phosphate dehydrogenase (GAPD), was 
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also present in the reaction mixture to catalyze the following reaction: 
1,3-Diphosphoglycerate + NADH ~ Q M D . _ • Glyceraldehyde-3-P + NAD + P 
By determining the decrease in absorbance at 340nm that resulted when NADH 
was oxidized to NAD, a measure of the amount of ATP originally present was 
obtained. 
Procedure for detecting the ATP content in cells after antisense treatment 
5x 105 HepG2 cells or 6x 10^  R-HepG2 cells in 2 ml complete medium were 
seeded on 6-well plate per well and incubated at 37 5 % CO� overnight. Then, 
the cells were transfected with oligo/lipofectin complex for 15 hours. After 24 hrs, 
48 hrs or 72 hrs post-incubation with fresh complete medium, adensoine-5,-
triphosphate (ATP) assay was carried out. First, medium was discarded and the cells 
were washed with PBS twice. Then, cells were trypsinized and then centrifuged at 
lOOOx g for 3 minutes. The cell pellet was then washed with PBS once. Finally, 
the cell pellet was resuspended and lysed in 55 |LI1 12% trichloroacetic acid solution 
(TCA) and incubated at 4 � C for 10 minutes. The protein-free supernatant was 
obtained by centrifliging at 5000x g for 15 minutes at 4 Then, ATP content in the 
protein-free supernatant was determined by using a Sigma diagnostics kit while the 
TCA pellet was resuspended in 200 |LI1 0.1% sodium dodecyl sulfate (SDS) with 1% 
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IM NaOH. Volume of 5 |LI1 of the SDS solution was then used to determine the 
protein amount by bicinchoninic acid assay (BCA) (referred to section 2.2.1.8 
Western blotting for protein determination). Samples were tested in triplicate. For 
ATP determination using an assay kit, 0.3mg NADH was first mixed with 1ml PGA 
buffered solution (consisting of 18mM 3-phosphoglyceric acid, magnesium ions and 
EDTA) and 1.7 ml deionized water. Then, 450 |LI1 of the above reaction mixture was 
mixed well with 50 [i\ of the supernatant in the tested sample. Then, absorbance was 
read and recorded versus water as reference at 340nm by using a spectrophotometer. 
This reading was the initial absorbance. The enzymatic reaction was started by 
adding 6.7 |LI1 enzyme mixture (glyceraldehyde phosphate dehydrogenase (GAPD) 
and phosphoglycerate phosphokinase (PGK)). After 10 minutes, the final 
absorbance was recorded at 340nm. 
Statistical calculations 
An ATP standard curve (change in absorbance at 340nm versus different 
concentration of ATP) should be plotted. Then, the ATP concentration in cells was 
calculated as follows: 
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ATP concentration (|LIM / mg protein)= 
change in absorbance / slope of standard curve 
protein concentration of the TCA pellet (mg) 
2.2.1.8 Western blot analysis 
Total protein extraction from cells 
5x 10' HepG2 cells or 6x 10' R-HepG2 cells in 2 ml complete medium were 
seeded on 6-well plate per well and incubated at 37 5 % CO2 overnight. Then, 
transfection was performed. After 24 hrs, 48 hrs or 72 hrs post-incubation, the cells 
were used for protein preparation. Cells were trypsinized and washed with PBS 
twice. Cell pellet was then obtained by centrifuging at lOOOx g for 3 minutes. 
Lysis buffer (1 % (w/v) SDS, ImM NasVO*, 10 mM Tris, 5 mM MgCl^, 21 jug/ml 
aprotinin, 5 |ig/ml leupeptin, 1 mM PMSF and pH = 7.4) at volume of 100 )LI1 was 
added to lyse the cells. The mixture was mixed well and stood in ice bath for 30 
minutes. Subsequently, the samples were boiled for 10 minutes and stored at —70 
Determination of protein amount by bicinchoninic acid assay (BCA) 
After protein extraction, it was necessary to assess the amount of total protein 
extracted by SDS lysis buffer by using bicinchoninic acid assay (BCA). All samples 
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were added in 96-well plate. Volume of 1 jjJ of protein sample was mixed with 9 
of PBS. Protein standard was made by different amount of bovine serum albumin 
(BSA)，which was prepared in 2, 4，6, 8 and 10 jug per well. Both protein samples 
and BSA protein standard were done in triplicate. BCA mixture was prepared by 
mixing BCA (bicinchoninic acid solution) and CUSO4-5H2O solution in the ratio of 
50:1. Then, 200 of BCA mixture was added to each well and incubated at 37°C 
for 30 minutes. Besides, BCA mixture was set as blank. After 30 minutes, 
absorbance was read at wavelength 540nm by microplate reader. Finally, the protein 
amount in samples could be calculated from the protein standard curve (optical 
density at 540nm versus protein amount). 
SDS poly aery lamide gel electrophoresis 
The protein mini-gel apparatus (Hoefer) vertical electrophoresis system was used. 
First, 12 0/0 separating gel buffer was prepared and the gel was set. Then, the gel 
solution was immediately overlaid with 70 % ethanol and allowed it to stand at room 
temperature for about 30 minutes. After that, the ethanol was discarded. Then, 
4.5 % stacking gel buffer was prepared and the gel was set with a comb inserted in it. 
The gel was then allowed to stand at room temperature for 15 minutes. On the other 
hand, the gel electrophoresis apparatus were set up and the gel tank was filled with 
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SDS running buffer. Subsequently, the comb was removed and the wells were 
washed with SDS running buffer. 
In each experiment, 25 )ig protein was used. First, protein sample was mixed 
with equal amount of 2 X SDS loading buffer (2 % (w/v) SDS, 10 % (w/v) sucrose, 
0.002 % bromophenol blue, 62.5 mM Tris and pH 6.8). Then, the samples were 
boiled for 5 minutes. Then, low range protein marker (BIO-RAD Laboratories) and 
samples were loaded to each well. Protein was run at constant voltage 200 V for 
about 1 hour until the bromophenol blue dye band was near to the lower end of the gel. 
After electrophoresis, gels were then soaked in electroblot buffer and ready for 
electroblotting onto membrane. 
Electroblotting of protein from gel onto membrane 
Electroblotting was done by using the apparatus of Semi-Dry Electrophoretic 
Transfer Cell (semi-dry transfer system, BIO-RAD Laboratories). 
Polyvinylidene fluoride (PVDF) microporous membrane (Immobilon, Millipore) 
was used for electroblotting. The dry PVDF membrane was soaked in absolute 
methanol for re-hydration. Then, membrane was soaked in electroblot buffer. 
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Besides, 1 mm filter paper (Whatman) was used for electroblotting. The filter paper 
should also be soaked in electxoblot buffer before electroblotting. The sequence of 
setup of semi-dry blotter for electroblotting was: cathode, 3 X filter paper, gel, PVDF 
membrane, 3 X filter paper, then anode. It was important to note that no air bubble 
was allowed in the set up. Electroblotting was done at 1 mA per 1 cm^ of membrane 
area for 1 hour in the semi-dry system. 
After electorblotting, gel was stained by commassie blue staining solution for 
overnight and de-stained with de-stain solution for another overnight. Besides, the 
membrane was used for probing of proteins with antibodies. 
Probing of proteins with antibodies 
The membrane was first used for non-specific blocking in 10 % non-fat milk (in 
TBS-T) at 4 � C overnight. Then, the membrane was washed with TBS-T for 15 min 
for three times. Subsequently, membrane was probed with primary polyclonal rabbit 
antibody against human Glut 2 (Santa Cruz Biotechnology, Inc.) in 2 ml 10% non-fat 
milk (antibody dilution 1:400) with constant shaking for 1 hour at room temperature. 
After probing with primary antibody, membrane was washed with TBS-T for 15 
minutes for three times. Membrane was then probed with secondary antibody 
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namely, anti-rabbit IgG antibody conjugated with horseradish peroxidase (Santa Cruz 
Biotechnology, Inc., U.S.A.) in 2 ml 10 % non-fat milk (antibody dilution 1:400) for 
further 1 hour at room temperature with constant shaking. Finally, the membrane 
was washed with TBS-T for 15 minutes for three times. Membrane was then ready 
for development by using chemiluminescent detection assay. 
Enhanced chemiluminescence (ECL) assay 
Enhanced chemiluminescence (ECL) detection reagents were used in this assay 
(Amersham Pharmacia Biotech, U.S.A.). 
Membrane was probed with ECL reagent mixture (reagent 1 plus reagent 2 in the 
ratio of 1:1) (Amersham Pharmacia Biotech, U.S.A.) for 1 minute at room 
temperature. Membrane was then wrapped in saran wrap and the emitting signal 
was detected by exposure to autoradiography film -- Fuji Medical x-ray film (super 
Rx, Fuji, Japan) for various time courses. Films were then processed in film 
processor (M35 X-OMAT, Kodak, U.S.A.). The band intensity was quantified by 
using densitometer (Molecular Dynamics, U.S.A.). Images were analyzed by 
Molecular Dynamics, ImageQuaNT, version 4.1. 
Chapter 2 Materials and Methods Page 55 
2.2.2 In vivo studies 
/« vivo experiments were designed to investigate the effect of antisense 
oligonucleotide on animal models (nude mice). 
2.2.2.1 Animal studies 
Subcutaneous inoculation of HepG2 or R-HepG2 cells in nude mice 
4x 10' HepG2 or R-HepG2 cells in 0.2 ml PBS was inoculated subcutaneously 
(s.c.) into the anterior part of each athymic BALB/c nude mouse and allowed the cells 
to grow for 2 days. Treatments were then started 2 days after implantation ofHepG2 
cells or R-HepG2 cells into nude mice, 
f, ^ , — — 、 … — 一 ， — — 
^ „ , A picture of nude mice before 
/ m I * 一 � implantation of cancer cells 
^ ^ ^ 發 T u m o r grew at the back of nude mice. 
脚 _ 
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Treatment schedules 
Mice were randomly divided into four groups (7 mice per group). The four 
groups were: (i) antisense group, (ii) sense group, (iii) saline group (the control group) 
and (iv) negative control group. In the first three groups, HepG2 or R-HepG2 cells 
were inoculated while for the negative control group no cell was implanted. 
For the first two groups, phosphorothioated oligonucleotides (antisense or sense) 
dissolved in autoclaved saline (0.9% NaCl) at dosage of 5 mg/kg/injection were 
injected subcutaneously adjacent to the tumor into each nude mouse for successive 5 
days. Autoclaved saline was injected instead for the control saline group while 
nothing was injected for the negative control group. Drugs were administered 
subcutaneously into tumor bearing mice with constant volume of 0.2 
ml/mouse/inj ection. 
After 5 days treatment, mice were sacrificed on the sixth day. Tumor weight 
was measured. Besides, effects of the drugs on normal tissues were assessed. 
Tissue damage such as heart or liver would result in release of sizable amount of 
enzymes such as lactate dehydrogenase (LDH)，creatine kinase (CK), aspartate 
transaminase (AST) and alanine transaminase (ALT) into systemic circulation. As 
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tissue damage such as heart or liver was accompanied with an elevation of one or 
more of the above enzymes in plasma, measurement of serum enzymatic activity was 
used as a diagnostic tool to detect tissue damage. The enzymatic activities were 
performed by using four different assay kits (Sigma). 
Sacrifice of nude mice 
HepG2 or R-HepG2 cells bearing nude mice were anesthetized bv intra-
peritoneal (i.p.) injection of 0.1 ml pentobarbital (25 mg/ml and dissolved in saline). 
Then, a 25G syringe, which was pre-rinsed with heparin solution (50 units/ml and 
dissolved in PBS), was injected into the heart directly and withdrew the whole blood 
from each mouse. About 0.8ml to 1 ml whole blood was collected and was 
immediately transferred to 1.5-ml microtube. Red blood cells and plasma were 
separated by centrifugating at 200x g for 15 minutes at 4 � C . Then, plasma at the 
upper layer was collected and transferred to a new microtube and enzymatic assays 
were performed. It was important to note that hemolyzed samples were not suitable 
for assays. On the other hand, tumor was taken out and its weight was measured. 
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Enzymatic assays to determine any damage done on normal tissues by the drugs 
delivered to mice 
(i) Lactate dehydrogenase (LDH) assay (Sigma) 
Introduction 
Lactate dehydrogenase (LDH) activity was significantly elevated during 
myocardial infarction. Besides, rises in LDH activity were also associated with 
many other pathologic conditions including various liver diseases and pernicious 
anemia. As a result, this could specifically determine whether there was any damage 
done on heart of the nude mice treated with drugs. 
Principle 
The following reaction was catalyzed by lactate dehydrogenase (LDH): 
Lactate + NAD ^ ^ • Pyruvate + NADH 
LDH catalyzed the oxidation of lactate to pyruvate with simultaneous reduction 
of nicotinamide adenine dmucleotide (NAD). Formation of reduced nicotinamide 
adenine dmucleotide (NADH) resulted in an increase in absorbance at wavelength 
340nm. The rate of increase in absorbance at 340nm was directly proportional to the 
LDH activity in the plasma sample. 
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Procedure 
1 ml of the lactate dehydrogenase (LDH) reagent was mixed with 50 jitl plasma 
sample in a cuvet. Then, the cuvet was placed immediately in 30 cuvet 
compartment for 30 seconds. Absorbance was then read and recorded at 340nm 
versus deionized water as reference. This was the initial absorbance. The cuvet 
was kept at the 30 °C cuvet compartment and absorbance was continuously recorded 
exactly 30 seconds and 60 seconds following the initial absorbance reading. The 
absorbance reading after 60 seconds was the final absorbance. Readings taken at 30-
second intervals were used to check the linearity of the reaction rate. 
Statistical calculations 
LDH activity was calculated as follows: 
LDH activity (U/L) 二 dA per min x TV x 1000 
6.22 X SV X LP 
where: 
dA per min = Change in absorbance per minute at 340nm 
TV = Total reaction mixture volume (1.05 ml) 
SV = Sample volume (0.05 ml) 
6.22 = Millimolar absorptivity of NADH at 340nm 
LP = Lightpath (1 cm) 
1000 = Conversion of units per ml to units per liter 
LDH activity (U/L) = dA per min x 1.05 x 1000 
6.22 X 0.05 
=dA per min x 3376 
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One unit of activity was defined as the amount of enzyme that would catalyze the 
formation of one micromole of NADH per minute under the conditions of the assay 
procedure. 
(ii) Creatine Kinase (CK) assay (Sigma) 
Introduction 
Cardiac muscle injury following myocardial infarction resulted in a rise in serum 
CK activity. Moreover, elevated serum CK activity was also found in various types 
of muscular dystrophy, hypothyroidism, viral myositis and similar muscle diseases. 
Thus, measurement of serum CK activity was used as a diagnostic tool to detect 
myocardial infarction and various forms of muscle disease. 
Principle 
The enzymatic reactions involved in this assay were as follows: 
Creatine Phosphate + ADP ——— • Creatine + ATP 
ATP + Glucose • ADP + G-6-P 
G-6-P + NAD Q-6-PDH ^ 6-PG + NADH 
CK catalyzed the reaction between creatine phosphate and adenosine 
diphosphate (ADP), forming creatine and adenosine triphosphate (ATP). The ATP 
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formed was used to phosphorylate glucose, producing glucose-6-phosphate (G-6-P) in 
the presence ofhexokinase (HK). Then, G-6-P was oxidized to 6-phosphogluconate 
(6-PG) in the presence of NAD and this reaction was catalyzed by glucose-6-
phosphate dehydrogenase (G-6-PDH). During this oxidation, an equimolar amount 
of NAD was reduced to NADH increasing the absorbance at 340nm. The rate of 
change in absorbance was directly proportional to CK activity. 
Procedure 
1 ml creatine kinase reagent was mixed with 0.02 ml serum sample in a cuvet. 
Then, the cuvet was placed in 30 cuvet compartment and incubated for 3 minutes. 
Then, initial absorbance was read and recorded at 340nm versus water as reference. 
The cuvet was kept at the 30 cuvet compartment and absorbance was continuously 
recorded at 30-second intervals for 120 seconds and the absorbance reading at 120 
seconds was the final absorbance. Readings taken at 30-second intervals were used 
to check the linearity of the reaction rate. 
Statistical calculations 
CK activity was calculated as follows: 
CK (U/L) = dA per min x TV x 1000 
6.22 X LP X SV 
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where: 
dA per min = Change in absorbance per minute at 340nm 
TV = Total volume (ml) 
SV = Sample volume 
6.22 = Millimolar absorptivity of NADH at 340nm 
LP = Lightpath 
1000 = Conversion of units per ml to units per liter 
CK (U/L) = dA per minute x 1.02 x 1000 
6.22 X 0.02 
=dA per minute x 8200 
One unit of activity was defined as the amount of enzyme that would catalyze the 
formation of one micromole of NADH per minute under the conditions of the assay 
procedure. 
(Hi) Aspartate transaminase (AST) assay (Sigma) 
Introduction 
AST was widely distributed with high concentration in heart, liver, skeletal 
muscle, kidney and erythrocytes. Damage or disease to any of these tissues such as 
myocardial infarction, liver necrosis and muscular dystrophy would result in an 
elevation of serum AST level. Thus, measurement of serum AST activity was used 
as a diagnostic tool to detect heart, liver, kidney and muscular injuries in present 
study. 
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Principle 
The enzymatic reactions involved in this assay were as follows: 
AST 
L-Aspartate + 2-Oxoglutarate ^ ^ • Oxalacetate + L-Glutamate 
Oxalacetate + NADH —————•L-Malate + NAD 
AST catalyzed the transfer of the amino group from L-aspartate to 2-
oxoglutarate forming oxalacetate and L-glutamate. The oxalacetate was then 
reduced to L-malate in the presence of malate dehydrogenase (MD). In this reaction, 
NADH was oxidized to NAD. The rate of decrease in absorbance at 340nm was 
directly proportional to AST activity. 
Procedure 
1 ml AST reagent was mixed with 0.1 ml sample in a cuvet. Then, the cuvet 
was placed in 3 7 � C cuvet compartment and incubated for 60 seconds. Then, initial 
absorbance was read and recorded at 340nm versus water as reference. The cuvet 
was kept at the 3 7 � C cuvet compartment and absorbance was continuously read 
exactly after 30 seconds and 60 seconds following initial absorbance reading. The 
absorbance reading after 60 seconds was the final absorbance. Readings taken at 30-
second intervals were used to check the linearity of the reaction rate. 
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Statistical calculations 
AST activity was calculated as follows: 
AST (U/L) = dA per min x TV x 1000 
6.22 X SV X LP 
where: 
dA per min = Change in absorbance per minute at 340nm 
TV = Total volume (1.1ml) 
SV = Sample volume (0.1ml) 
6.22 = Millimolar absorptivity of NADH at 340nm 
LP = Lightpath (1 cm) 
1000 = Conversion of units per ml to units per liter 
AST activity (U/L) = dA per minx 1.1 x 1000 
6.22x0.1 X 1.0 
=dA per minx 1768 
One unit of activity was defined as the amount of enzyme that produced one 
micromole of NAD per minute under the conditions of the assay procedure. 
(iv) Alanine transaminase (ALT) assay (Sigma) 
Introduction 
ALT was present in high concentration in the liver and to a lesser extent in 
kidney, heart, skeletal muscle, pancreases, spleen and lung. However, increased 
levels of ALT were generally a result of liver damage. Elevated ALT levels had also 
been found in extensive trauma and muscle disease, circulatory failure with shock, 
hypoxia, myocardial infarction and hemolytic disease. Thus, measurement of ALT 
activity in serum sample could be used specifically to detect liver injury. 
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Principle 
The enzymatic reactions involved in the assay were as follows: 
ATT 
L-Alanine + 2-Oxoglutarate ^ ^ • Pyruvate + L-Glutamate 
Pyruvate + NADH L D H _ ^ L-Lactate + NAD 
ALT catalyzed the transfer of the amino group from alanine to 2-oxoglutarate to 
form L-glutamate and pyruvate. Then, pyruvate was reduced to lactate in the 
presence of lactate dehydrogenase with the simultaneous oxidation of NADH to NAD. 
The rate of decrease in absorbance at 340nm was directly proportional to ALT 
activity. 
Procedure 
1 ml ALT reagent was mixed with 0.1 ml sample in a cuvet. Then, the cuvet 
was placed in 30 °C cuvet compartment and incubated for 90 seconds. Then, initial 
absorbance was read and recorded at 340nm versus water as reference. The cuvet 
was kept at the 3 0 � C cuvet compartment and absorbance was continuously read 
exactly at 30 seconds and 60 seconds following initial absorbance reading. The 
absorbance reading at 60 seconds was the final absorbance. Readings taken at 30-
second intervals were used to check the linearity of the reaction rate. 
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Statistical calculations 
ALT activity was calculated as follows: 
ALT (U/L) = dA per minute x TV x 1000 
6.22 X LP X SV 
where: 
dA per min = Change in absorbance per minute at 340nm 
TV = Total volume (1.1ml) 
SV 二 Sample volume (0.1ml) 
6.22 = Millimolar absorptivity of NADH at 340nm 
LP = Lightpath (1 cm) 
1000 = Conversion of units per ml to units per liter 
ALT (U/L) = dA per minute x 1.1 x 1000 
6.22 X 1.0x0.1 
=dA per minute x 1768 
One unit of activity was defined as the amount of enzyme that produced one 
micromole of NAD per minute under the conditions of the assay procedure. 
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Chapter 3 
Results 
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Chapter 3 Results 
3.1 In vitro studies 
3.1.1 Characteristics of the multi-drug resistant cell line (R-HepG2) developed in 
our laboratory 
Multi-drug resistant cell line (R-HepG2) was developed in our laboratory by 
incubating HepG2 cells in stepwisely increased concentrations of doxorubicin 
(Sigma). When R-HepG2 cells were treated with different concentrations of 
doxorubicin, ranging from 1-10 |LIM, for 24 hr and 48 hr, not much cell death was 
observed and the percentage of cell viability after each treatment was approximately 
100%. On the other hand, cytotoxicity of doxorubicin on HepG2 cells after 48 hr 
incubation was greater than that after 24 hr incubation. The IC50 (drug concentration 
to make half number of cells lethal) of the parental HepG2 cells were found to be 5.8 
|LIM and 1.2 ]iM after incubating with doxorubicin for 24 hr and 48 hr respectively 
(figure 3.1 and 3.2). 
Although the resistant cell line was developed by incubating with increasing 
concentrations of doxorubicin only, R-HepG2 was a multi-drug resistant cell line as 
Chapter 3 Results Page 69 
the IC50 of another two anticancer drugs (vincristine and methotrexate) on R-HepG2 
in 48 hr incubation also increased significantly when compared with those in parental 
HepG2 cells (table 3.1). 
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Figure 3.1 Cytotoxicity of doxorubicin on HepG2 and R-HepG2 after 24 hr 
incubation 
2x104 cells/well were seeded on 96-well plate. Different concentrations (0-10 j^ M) 
of doxorubicin were added to the cells and incubated for 24 hr. Cell viability was 
then measured by MTT assay. Cell viability was compared with the negative control 
in which the cells were incubated with complete medium only. 
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Figure 3.2 Cytotoxicity of doxorubicin on HepG2 and R-HepG2 after 48 hr 
incubation 
2x104 cells/well were seeded on 96-well plate. Different concentrations (0-10 |LIM) 
of doxorubicin were added to the cells and incubated for 48 hr. Cell viability was 
then measured by MTT assay. Cell viability was compared with the negative control 
in which the cells were incubated with complete medium only. 
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“ HepG2 R-HepG2 
Vincristine 3.5 ^iM 150 jiiM 
Methotrexate 30 jiiM 120 [iM 
Table 3.1 Determination of IC50 of different anticancer drugs after 48 hr 
incubation (no. of trials = 3，eight data for each treatment was performed) 
(adapted from Chan et al., 2000). 
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Another characteristic of the multidrug resistant cell line (R-HepG2) is the 
expression of P-glycoprotein encoded by human MDR 1 gene (figure 3.3) (Chan et al., 
2000). It is a high molecular weight membrane protein of size 170 kDa. P-
glycoprotein is a member of ATP-dependent transport protein (figure 3.4). It 
functions as an active multidrug extruding agent by using the energy provided by ATP 
and thus decreases the intracellular accumulation of drug. 
In order to investigate the pumping effect of P-glycoprotein on antitumor drugs, 
the intracellular accumulation of doxorubicin in both HepG2 and R-HepG2 were 
measured by flow cytometry. After incubation with 1.2 i^M doxorubicin for 24 hr, it 
was found that the amount of doxorubicin retained in HepG2 was twice as much as 
that ofR-HepG2 (figure 3.5). Besides, it was found that when R-HepG2 cells were 
treated with antisense RNA against MDR 1 gene, the ability of intracellular 
doxorubicin retention increased and drug efflux decreased (Chan et al., 2000). Thus, 
doxorubicin retention inside R-HepG2 cells was probably due to the pumping effect 
of P-glycoprotein on the drug. 
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beta-actin I I R F 
Figure 3.3a Expression of MDR 1 mRNA in HepG2 and R-HepG2 cells (adapted 
from Chan et al, 2000). 
HepG2 R-HepG2 
170 kDa ^ ^ m m i l ^ 
Figure 3.3b Western blot analysis of P-glycoprotein in HepG2 and R-HepG2 
(adapted from Chan et al.’ 2000). 
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Figure 3.4 Possible mechanism of action of drug efflux by P-glycoprotein (adapted 
from Johnstone et al., 2000). 
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Figure 3.5 Comparison of intracellular accumulation of doxorubicin in HepG2 
and R-HepG2 cells. 
5x 10^  HepG2 cells/well or 6x 10^  R-HepG2 cells/well were seeded on 6-well plate 
overnight. Then 1.2 fiM doxorubicin was added to the cells and incubated for 24 hr. 
The intracellular doxorubicin content was measured by flow cytometry and the mean 
fluorescence intensity (Gm value) was calculated using the program WinMDI 2.6. 
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3.1.2 Effect oflipofectin on cell viability 
Antisense oligonucleotides (ODNs) complementary to specific mRNA sequences 
are widely used as gene expression inhibitors by forming a hybrid duplex with the 
target nucleotide sequence. Thus, it is important to ensure the entry of antisense 
ODNs into cells so they can exert their biological effects on the target sites. 
However, a problem affecting antisense ODNs efficiency is their poor cellular uptake 
into cells as the oligonucleotides are negatively charged and their cell permeability is 
low. Therefore, a delivery system must be used to enhance the uptake of 
oligonucleotides into cells. In cell culture studies, cationic liposome is one of the 
most widely used delivery carriers. In this experiment, commercially available 
cationic liposome known as lipofectin was used. Lipofectin Reagent is a 1:1 (w/w) 
liposome formulation of the cationic lipid N-[l-(2,3-dioleyloxy)propyl]-n,n,n-
trimethylammonium chloride (DOTMA), and dioleoyl phosphotidylethanolamine 
(DOPE). This liposome can interact spontaneously with DNA to form a lipid-DNA 
complex. The formation of the complex is by the ionic interaction between the 
positively charged groups on DOTMA and the negatively charged phosphate groups 
on the oligonucleotide. DOPE is used to help in the release of oligonucleotides from 
the endosome compartment of cells. 
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Before investigating the cellular uptake of oligonucleotides in the presence of 
lipofectin, toxicity of lipofectin was tested on HepG2 and R-HepG2 cell lines. The 
toxicity was tested on both cell lines for a range of lipofectin concentrations (0 to 8 jug 
per well) and incubated for different periods of time (5hr, 15hr and 24hr) (Figure 3.6 
to 3.8). It was found that lipofectin was toxic when it was used at high concentration 
and after a prolonged incubation time. For 5 hr incubation, the percentage of cell 
survival was greater than 80%. For 15 hr incubation, more than 80% were viable 
cells when 0-4 i^g lipofectin was used. For 24 hr incubation, the percentage of cell 
survival smaller than 80% was observed in both cell lines even when 2 |Lig lipofectin 
was used. 
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Figure 3.6 Cytotoxic effect of lipofectin on HepG2 and R-HepG2 after incubating 
lipofectin at various concentrations for 5 hours. 
1x104 cells/well were seeded on 96-well plate. Different concentrations of lipofectin 
in 100 serum-free medium were added to the cells and incubated for 5 hr. The 
cells were then washed with serum-free medium and replaced with fresh complete 
medium for further 48 hr incubation. Cell viability was then measured by MTT 
assay. Cell viability was compared with the negative control in which the cells were 
incubated with serum-free medium only. 
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Figure 3.7 Cytotoxic effect of lipofectin on HepG2 and R-HepG2 after incubating 
lipofectin at various concentrations for 15 hours. 
Ixl04 cells/well were seeded on 96-well plate. Different concentrations of lipofectin 
in 100 [il serum-free medium were added to the cells and incubated for 15 hr. The 
cells were then washed with serum-free medium and replaced with fresh complete 
medium for further 48 hr incubation. Cell viability was then measured by MTT 
assay. Cell viability was compared with the negative control in which the cells were 
incubated with serum-free medium only. 
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Figure 3.8 Cytotoxic effect of lipofectin on HepG2 and R-HepG2 after incubating 
lipofectin at various concentrations for 24 hours. 
1x104 cells/well were seeded on 96-well plate. Different concentrations of lipofectin 
in 100 |al serum-free medium were added to the cells and incubated for 24 hr. The 
cells were then washed with serum-free medium and replaced with fresh complete 
medium for further 48 hr incubation. Cell viability was then measured by MTT 
assay. Cell viability was compared with the negative control in which the cells were 
incubated with serum-free medium only. 
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3.1.3 Cellular uptake of antisense oligonucleotide 
In order to determine whether lipofectin could enhance the uptake of 
oligonucleotides into HepG2 and R-HepG2 cells, internalization of phosphorothioated 
FITC-labeled oligonucleotides into both cell lines was measured by flow cytometric 
method. Cells were seeded on 6-well plate. For negative control, only serum and 
antibiotic free medium was used. Then, uptake of FITC oligonucleotides in the 
presence and absence of lipofectin were studied and compared. In the presence of 
lipofectin, antisense oligonucleotides at 4 jiiM was first mixed with lipofectin in a 
ratio of 1:1 (w/w) and then added to cells for different transfection time (8 hr, 12 hr, 
15 hr, 18 hr and 24 hr) while only 4 |LIM FITC oligonucleotides was added if no 
lipofectin was used. 
Figure 3.9 and figure 3.10 show the results of typical experiments. It was found 
that lipofectin enhanced the uptake of FITC-oligonucleotides in HepG2 and R-HepG2 
cells when compared with that observed when FITC-labeled oligonucleotide was used 
alone. Thus, the carrier system, lipofectin, could ensure a successful delivery of 
antisense oligonucleotides into cells. When the Gm value of fluorescence intensity 
was plotted against transfection time, it was found that the amount of FITC-labeled 
oligonucleotide taken up by cells increased when the transfection time increased from 
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8 hr to 15 hr in the presence of lipofectin (figure 3.11). However, the amount of 
oligonucleotide taken up by cells began to decrease gradually at 18 hr or 24 hr 
transfection time. On the other hand, the amount of oligonucleotides taken up by 
cells in the absence of lipofectin did not increase with transfection time. Instead, 
uptake of oligonucleotide without using lipofectin was quite constant when the 
transfection time increased from 8 hr to 24 hr and the amount of uptake was relatively 
low when compared with that observed when lipofectin was used. 
As the greatest amount of oligonucleotide was taken up by cells at 15 hr 
transfection and the lipofectin toxicity at 15 hr incubation was relatively low with the 
cell viability of lipofectin treated cells was equal to or greater than 80% of the 
untreated cells when amount of lipofectin used was equal to or smaller that 4 \ig 
(figure 3.7). Thus, the transfection time was set to be 15 hours. 
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Figure 3.9 Effect of lipofectin on the uptake of FITC-labeled oligonucleotide in 
HepG2 and R-HepG2 cells. 
5x 10' HepG2 or 6x 10' R-HepG2 cells/well were seeded on 6-well plate. Then, 4 
FITC oligonucleotides were mixed with lipofectin in a ratio of 1:1 (w/w) in serum 
free medium and then added to the cells for 8 hr or 12 hr transfection. Uptake of 
FITC oligonucleotides were measured by flow cytometry and the mean fluorescence 
intensity (Gm value) was calculated using the program WinMDI 2.6. 
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Figure 3.10 Effect of lipofectin on the uptake of FITC-labeled oligonucleotide in 
HepG2 and R-HepG2 cells. 
5x 10^  HepG2 or 6x 10^  R-HepG2 cells/well were seeded on 6-well plate. Then, 4 
|j-M FITC oligonucleotides were mixed with lipofectin in a ratio of 1:1 (w/w) in serum 
free medium and then added to the cells for 15 hr, 18 hr or 24 hr transfection. 
Uptake of FITC oligonucleotides were measured by flow cytometry and the mean 
fluorescence intensity (Gm value) was calculated using the program WinMDI 2.6. 
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Figure 3.11 Gm value of fluorescence intensity was plotted against transfection 
time. 
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3.1.4 Effect of Glut 2 antisense oligonucleotides on human hepatoma HepG2 and 
its multidrug resistant (R-HepG2) cells by MTT assay 
The effect of phosphorothioated antisense oligonucleotides against Glut 2 in both 
HepG2 and R-HepG2 cells were investigated. In this experiment, Glut 2 sense 
oligonucleotides were used as a control while cells treated with serum free medium 
only was the negative control. Sense oligonucleotides were used as the control to 
indicate if there was any non-specific effect caused by transfection. First, various 
concentrations of Glut 2 sense or antisense oligonucleotides were mixed with 
lipofectin in a ratio of 1:1 (w/w) in serum free medium. Then, they were added to 
cells and incubated at 37 for 15 hr. After transfection, the serum free medium 
was replaced by complete medium and further incubated for 24 hr, 48 hr and 72 hr. 
Then, cell viability was studied by MTT assays. 
It was found that the effect of antisense oligonucleotides was concentration 
dependent for 24 hr, 48 hr and 72 hr post-incubation in both HepG2 (figure 3.12 to 
3.14) and R-HepG2 cells (figure 3.15 to 3.17). Besides, the greatest effect was 
found after 48 hr post-incubation for both cell lines. 
For 24 hr post-incubation, Glut 2 antisense oligonucleotides caused 8% to 58% 
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cell death when 1 |LIM to 8 |LIM oligonucleotides were used in HepG2 while the effect 
of sense control also increased with concentration. In R-HepG2, antisense caused 
9.4% to 55% cell death when the concentration of antisense increased from 1 |LIM to 8 
jiM at 24 hr post incubation. 
After 48 hr post-incubation, the percentage of cell viability decreased from 85% 
to 14% in HepG2 when antisense concentration increased from 1 jiiM to 8 jiM. 
Since the effect of the sense control was relatively high (smaller than 50% cell 
viability) when 6 |iM and 8 |iM sense oligonucleotides were used, antisense 
concentration was set to be 4 ^M at which there was about 70% viable cells in sense 
control. 
In R-HepG2, the percentage of cell survival decreased from 80% to 21% after 48 
hr recovery period when antisense concentration increased from 1 |aM to 8 \iM. 
When 6 yiM and 8 [iM sense oligonucleotides were used, there were only 56% and 
440/0 viable cells respectively. Therefore, antisense concentration was set to be 4 ^M 
at which the sense effect was relatively low. 
At 72 hr post incubation, the effect of antisense seemed to recover. Glut 2 
Chapter 3 Results Page 89 
antisense oligonucleotides caused 6% to 60% cell death when 1 jiM to 8 jiM 
oligonucleotides were used in HepG2. In R-HepG2, antisense oligonucleotides 
caused 15% to 53% cell death when its concentration increased from 1 JUM to 8 )LIM. 
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Figure 3.12 Effect of antisense oligonucleotides against Glut 2 on HepG2 cell 
viability after 24 hr post-incubation. 
1x104 HepG2 cells were seeded on 96-well plates. Different concentration of 
antisense and sense oligonucleotides (ODNs) were complexed with lipofectin in a 
ratio of 1:1 (w/w) in serum free medium and added to cells. After 15 hr transfection, 
cells were incubated with complete medium for further 24 hr. Percentage of cell 
viability relative to serum free treated negative control was measured by MTT assays. 
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Figure 3.13 Effect of antisense oligonucleotides against Glut 2 on HepG2 cell 
viability after 48 hr post-incubation. 
1x104 HepG2 cells were seeded on 96-well plates. Different concentrations of 
antisense and sense oligonucleotides (ODNs) were complexed with lipofectin in a 
ratio of 1:1 (w/w) in serum free medium and then added to cells. After 15 hr 
transfection, cells were incubated with complete medium for further 48 hr. 
Percentage of cell viability relative to serum free treated negative control was 
measured by MTT assays. 
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Figure 3.14 Effect of antisense oligonucleotides against Glut 2 on HepG2 cell 
viability after 72 hr post-incubation. 
Ixl04 HepG2 cells were seeded on 96-well plates. Different concentrations of 
antisense and sense oligonucleotides (ODNs) were complexed with lipofectin in a 
ratio of 1:1 (w/w) in serum free medium and added to cells. After 15 hr transfection, 
cells were incubated with complete medium for further 72 hr. Percentage of cell 
viability relative to serum free treated negative control was measured by MTT assays. 
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Figure 3.15 Effect of antisense oligonucleotides against Glut 2 on R-HepG2 cell 
viability after 24 hr post-incubation. 
2x104 R-HepG2 cells were seeded on 96-well plates. Different concentrations of 
antisense and sense oligonucleotides (ODNs) were complexed with lipofectin in a 
ratio of 1:1 (w/w) in serum free medium and added to cells. After 15 hr transfection, 
cells were incubated with complete medium for further 24 hr. Percentage of cell 
viability relative to serum free treated negative control was measured by MTT assays. 
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Figure 3.16 Effect of antisense oligonucleotides against Glut 2 on R-HepG2 cell 
viability after 48 hr post-incubation. 
2xl04R-HepG2 cells were seeded on 96-well plates. Different concentrations of 
antisense and sense oligonucleotides (ODNs) were complexed with lipofectin in a 
ratio of 1:1 (w/w) in serum free medium and added to cells. After 15 hr transfection, 
cells were incubated with complete medium for further 48 hr. Percentage of cell 
viability relative to serum free treated negative control was measured by MTT assays. 
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Figure 3.17 Effect of antisense oligonucleotides against Glut 2 on R-HepG2 cell 
viability after 72 hr post-incubation. 
2x104 R-HepG2 cells were seeded on 96-well plates. Different concentrations of 
antisense and sense oligonucleotides (ODNs) were complexed with lipofectin in a 
ratio of 1:1 (w/w) in serum free medium and added to cells. After 15 hr transfection, 
cells were incubated with complete medium for further 72 hr. Percentage of cell 
viability relative to serum free treated negative control was measured by MTT assays. 
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3.1.5 Suppression of Glut 2 protein expression by antisense oligonucleotides as 
revealed by Western blot analysis 
In this project, the main purpose of using antisense oligonucleotides was to 
suppress protein expression of Glut 2 in both HepG2 and R-HepG2 cells. By means 
of Western blot analysis, which is a common technique used to determine the protein 
expression level of gene in cells, the change in protein level of Glut 2 after antisense 
treatment was investigated. 
Protein was extracted from cells at 24 hr, 48 hr and 72 hr post incubation. Then, 
25 i^ g protein was used for running 12% SDS PAGE. After blotting the protein onto 
a membrane, anti-rabbit human Glut 2 (1:400) was used to probe for Glut 2 and the 
fluorescent signal was detected on a film. Finally, the band intensity obtained from 
Western blot analysis was quantified by using a densitometer. 
Figure 3.18 and figure 3.19 show the results of typical experiments. It was 
found that the antisense oligonucleotides treated HepG2 and R-HepG2 cells expressed 
smaller amount of Glut 2. At 24 hr after transfection, protein expression level of 
Glut 2 was suppressed by 34% and 25% in HepG2 and R-HepG2 respectively in 
antisense treated cells when compared with that of the serum free control. The 
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degree of suppression increased at 48 hr after transfection. The percentage of 
protein suppression was found to be 43% and 37% in HepG2 and R-HepG2 
) 
respectively when compared with that of the serum free control. However, after 72 
hr post incubation, the effect of antisense decreased and the percentage of protein 
expression of Glut 2 was found to be 4.4% and 2.5% in HepG2 and R-HepG2 
respectively when compared with that of the serum free control. 
Chapter 3 Results Page 98 
24 hr post incubation 48 hr post incubation 
66% 100% 57% 100% 
丨 丨 I 隱 丨 圓 i � 4 0 kDa - I [ “ 
Antisense Control Antisense Control 




Figure 3.18 Suppression of Glut 2 protein expression level in HepG2 by antisense 
oligonucleotides as revealed by Western blot analysis 
5x 105 HepG2 cells/well were seeded on 6-well plate and incubated at 37 5 % CO2 
overnight. After transfection for 15 hr, cells were incubated with complete medium 
for 24, 48 and 72 hours. Then, protein was extracted and Western blot analysis was 
performed. Twenty-five jig protein was used for running 12% SDS PAGE. Protein 
on the gel was then blotted to a membrane. Anti-rabbit human Glut 2 (1:400) was 
used to probe for Glut 2 and the fluorescent signal was detected on a film. Finally, 
the film was processed and the band intensity obtained from Western blot analysis 
was quantified by using densitometer. 
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Figure 3.19 Suppression of Glut 2 protein expression level in R-HepG2 by 
antisense oligonucleotides as revealed by Western blot analysis 
6x 105 R_HepG2 cells/well were seeded on 6-well plate and incubated at 3 7 � C , 5 % 
CO2 overnight. After transfection for 15 hr, cells were incubated with complete 
medium for 24, 48 and 72 hours. Then, protein was extracted and Western blot 
analysis was performed. Twenty-five |Lig protein was used for running 12% SDS 
PAGE. Protein on the gel was then blotted to a membrane. Anti-rabbit human Glut 
2 (1:400) was used to probe for Glut 2 and the fluorescent signal was detected on a 
film. Finally, the film was processed and the band intensity obtained from Western 
blot analysis was quantified by using densitometer. 
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3.1.6 Uptake of glucose in HepG2 and R-HepG2 after Glut 2 antisense treatment 
Glut 2 is a facilitative glucose transporter. Since the protein expression level of 
Glut 2 was found to be suppressed after antisense treatment in our previous 
experiments, Glut 2 mediated glucose transport in the cells may also be reduced. 
Thus, 2-Deoxy-D-[l-^H] glucose uptake assay was performed to determine the 
intracellular activity of Glut 2 after antisense treatment. After treating the cells with 
antisense or sense oligonucleotides, they were incubated with complete medium for 
24, 48 and 72 hours. Then, O.lmM 2-deoxy-D-glucose and 1 |iCi 2-deoxy-D-[l-^H] 
glucose in 0.5ml PBS was added and incubated with cells for 15 minutes. Finally, 
cells were lysed and the amount of ^H-glucose uptake was measured by scintillation 
counter. Besides, volume of 10 |il cell lysate was used to determine the protein 
amount. Amount of ^H-glucose uptake was expressed as counts per minute (CPM)/ 
|Lig protein. 
It was found that the amount of glucose uptake in antisense treated cells were 
lower than that in sense control and serum free treated control at 24, 48 and 72 hours 
after transfection in HepG2 (figure 3.20 to 3.22). For 24 hr post incubation, uptake 
of glucose was suppressed by 37% in antisense treatment when compared with that of 
the serum free control. The activity of Glut 2 was further lowered at 48 hr post 
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incubation and it was found to have 54% reduction when compared with that of serum 
free control. For 72 hr post incubation, the effect of antisense was lower compared 
with those of 24 hr and 48 hr recovery period and the percentage of inhibition of 
glucose uptake was found to be 16% when compared with that of the serum free 
control. 
In R-HepG2, uptake of glucose in antisense treatment was lower when compared 
with sense control and serum free treated control (figure 3.23 to 3.25). Percentage of 
glucose uptake reduction was 29% at 24 hr after transfection when compared with 
that of serum free control. The amount of glucose uptake was significantly lower (p-
value < 0.05) after treating the cells with antisense oligonucleotides at 48 hr post 
incubation and activity of Glut 2 after antisense treatment was found to be lowered by 
45% when compared with that of serum free control. For 72 hr post incubation, the 
effect of antisense on glucose uptake decreased when compared with those of 24 hr 
and 48 hr post incubation and reduced glucose uptake by 15% when compared with 
that of serum free control. 
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Figure 3.20 Effect of Glut 2 antisense oligonucleotides on glucose uptake of 
HepG2 one day after transfection. 
5x 104 HepG2 cells/well in 0.5ml complete medium were seeded on 24-well plate. 
4 i^ M antisense or sense oligonucleotides complexed with lipofectin in a ratio of 1:1 
in serum free medium were incubated with cells for 15 hr. After further incubation 
in complete medium for one day, O.lmM 2-deoxy-D-glucose and 1 2-deoxy-D-
[1-^H] glucose in 0.5ml PBS was added to incubated with cells for 15 minutes. The 
amount of ^H-glucose uptake was expressed as counts per minute (CPM) per protein 
content Data were expressed as the mean of triplicate ：}： SD. The significance 
of the difference between the results of antisense treatment vs sense treatment was 
calculated by the Student's t-test (* p<0.05). Besides, the significance of the 
difference between the results of antisense treatment vs serum free treated control was 
calculated by the Student's t-test (# p<0.05). 
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Figure 3.21 Effect of Glut 2 antisense oligonucleotides on glucose uptake of 
HepG2 two days after transfection. 
5x 104 HepG2 cells/well in 0.5ml complete medium were seeded on 24-well plate. 
4 [iM antisense or sense oligonucleotides complexed with lipofectin in a ratio of 1:1 
in serum free medium were incubated with cells for 15 hr. After further incubation 
in complete medium for two days，O.lmM 2-deoxy-D-glucose and 1 jiCi 2-deoxy-D-
[1-^H] glucose in 0.5ml PBS was added to incubated with cells for 15 minutes. The 
amount of ^H-glucose uptake was expressed as counts per minute (CPM) per protein 
content (jag). Data were expressed as the mean of triplicate 土 SD. The significance 
of the difference between the results of antisense treatment vs sense treatment was 
calculated by the Student's t-test (* p<0.05). Besides, the significance of the 
difference between the results of antisense treatment vs serum free treated control was 
calculated by the Student's t-test (# p<0.05). 
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Figure 3.22 Effect of Glut 2 antisense oligonucleotides on glucose uptake of 
HepG2 three days after transfection. 
5x 104 HepG2 cells/well in 0.5ml complete medium were seeded on 24-well plate. 
4 |LIM antisense or sense oligonucleotides complexed with lipofectin in a ratio of 1:1 
in serum free medium were incubated with cells for 15 hr. After further incubation 
in complete medium for three days, O.lmM 2-deoxy-D-glucose and 1 jaCi 2-deoxy-D-
[1-^H] glucose in 0.5ml PBS was added to incubated with cells for 15 minutes. The 
amount of ^H-glucose uptake was expressed as counts per minute (CPM) per protein 
content (|ig). Data were expressed as the mean of triplicate 土 SD. The significance 
of the difference between the results of antisense treatment vs sense treatment was 
calculated by the Student's t-test (* p<0.05). Besides, the significance of the 
difference between the results of antisense treatment vs serum free treated control was 
calculated by the Student's t-test (# p<0.05). 
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Figure 3.23 Effect of Glut 2 antisense oligonucleotides on glucose uptake of 
R-HepG2 one day after transfection. 
6x 104 R-HepG2 cells/well in 0.5ml complete medium were seeded on 24-well plate. 
4 antisense or sense oligonucleotides complexed with lipofectin in a ratio of 1:1 
in serum free medium were incubated with cells for 15 hr. After further incubation 
in complete medium for one day, O.lmM 2-deoxy-D-glucose and 1 juCi 2-deoxy-D-
:1-3H] glucose in 0.5ml PBS was added to incubated with cells for 15 minutes. The 
amount of ^H-glucose uptake was expressed as counts per minute (CPM) per protein 
content Data were expressed as the mean of triplicate 土 SD. The significance 
of the difference between the results of antisense treatment vs sense treatment was 
calculated by the Student's t-test (* p<0.05). Besides, the significance of the 
difference between the results of antisense treatment vs serum free treated control was 
calculated by the Student's t-test (# p<0.05). 
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Figure 3.24 Effect of Glut 2 antisense oligonucleotides on glucose uptake of 
R-HepG2 two days after transfection. 
6x 104 R-HepG2 cells/well in 0.5ml complete medium were seeded on 24-well plate. 
4 [iM antisense or sense oligonucleotides complexed with lipofectin in a ratio of 1:1 
in serum free medium were incubated with cells for 15 hr. After further incubation 
in complete medium for two days，O.lmM 2-deoxy-D-glucose and 1 jiiCi 2-deoxy-D-
[1-^H] glucose in 0.5ml PBS was added to incubated with cells for 15 minutes. The 
amount of ^H-glucose uptake was expressed as counts per minute (CPM) per protein 
content Og). Data were expressed as the mean of triplicate 土 SD. The significance 
of the difference between the results of antisense treatment vs sense treatment was 
calculated by the Student's t-test (* p<0.05). Besides，the significance of the 
difference between the results of antisense treatment vs serum free treated control was 
calculated by the Student's t-test (# p<0.05). 
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Figure 3.25 Effect of Glut 2 antisense oligonucleotides on glucose uptake of 
R-HepG2 three days after transfection. 
6x 104 R-HepG2 cells/well in 0.5ml complete medium were seeded on 24-well plate. 
4 i^ M antisense or sense oligonucleotides complexed with lipofectin in a ratio of 1:1 
in serum free medium were incubated with cells for 15 hr. After further incubation 
in complete medium for three days, O.lmM 2-deoxy-D-glucose and 1 juCi 2-deoxy-D-
:1-3H] glucose in 0.5ml PBS was added to incubated with cells for 15 minutes. The 
amount of ^H-glucose uptake was expressed as counts per minute (CPM) per protein 
content (fag). Data were expressed as the mean of triplicate 土 SD. The significance 
of the difference between the results of antisense treatment vs sense treatment was 
calculated by the Student's t-test (* p<0.05). Besides, the significance of the 
difference between the results of antisense treatment vs serum free treated control was 
calculated by the Student's t-test (# p<0.05). 
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3.1.7 ATP content in HepG2 and R-HepG2 was lowered after treating the cells 
with antisense oligonucleotides 
Treating the cells with Glut 2 antisense oligonucleotides could lead to 
suppression of Glut 2 protein expression level and subsequently decreased the glucose 
uptake. Since glucose is the major source for ATP production, the effect of antisense 
treatment on ATP content in HepG2 and R-HepG2 cells was investigated. After 
transfection and recovery period, ATP assay was performed. The cell pellet was 
resuspended and lysed in 12% TCA solution. Then, protein-free supernatant was 
obtained by centrifugation and the ATP amount in the protein-free supernatant was 
determined by using a Sigma diagnostics kit while the TCA pellet was resuspended in 
0.1% SDS with 1% IM NaOH. On the other hand, a volume of 5 jiil of the SDS 
solution was used to determine the protein amount. The ATP concentration was then 
calculated from a standard curve (figure 3.26). Finally, ATP content in cells was 
expressed as the ATP concentration (|aM) per protein content (mg). 
For HepG2 cells (figure 3.27 to 3.29), the ATP content was reduced after 
antisense treatment at 24 hr, 48 hr and 72 hr recovery periods when compared with 
sense control and serum free control. ATP amount was lowered by 33% at 24 hr 
after transfection when compared with that of serum free control. The effect was the 
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greatest at 48 hr post incubation and the percentage of decrease in ATP content was 
found to be 55% when compared with that of serum free control. The effect of 
antisense began to recover at 72 hr post incubation as it only reduced 15% ATP 
amount in HepG2 cells when compared with that of serum free control. 
Glut 2 antisense oligonucleotides could decrease the ATP content in R-HepG2 
cells after 24, 48 and 72 hours post incubation (figure 3.30 to 3.32). It was found 
that antisense could lower the ATP amount by 26% at 24 hr post incubation when 
compared with that of the serum free control. The ATP amount was significantly 
lowered 48 hr after transfection and the percentage of decrease was 48% when 
compared with that of serum free control. After 72 hr post incubation, the antisense 
only exhibited a slight effect on R-HepG2 and the ATP content was reduced by 9.6% 
when compared with that of the serum free control. 
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Figure 3.27 Effect of antisense treatment on ATP content in HepG2 after 24 hr 
post incubation. 
5x10^ HepG2 cells/well were seeded on 6-well plate and treated with oligonucleotides 
(ODNs):lipofectin (1:1) complex for 15 hr. After 24 hr post incubation, ATP assay 
was carried out. The cell pellet was resuspended in 12% TCA solution. ATP 
amount in the protein-free supernatant was determined by using a Sigma diagnostics 
kit while the TCA pellet was resuspended in 0.1% SDS with 1% IM NaOH. 
Besides, 5 |LI1 of the SDS solution was used to determine the protein amount. The 
ATP concentration was then determined from an ATP standard curve. Finally, ATP 
content in cells was expressed as the ATP concentration (|aM) per protein content 
(mg). Data were expressed as the mean of triplicate samples 土 SD. The 
significance of the difference between the results of antisense treatment vs sense 
treatment was calculated by the Student's t-test (* p<0.05). Besides, the significance 
of the difference between the results of antisense treatment vs serum free treated 
control was calculated by the Student's t-test (# p<0.05). 
Chapter 3 Results Page 112 
I 200 
I : *# n i H 
5 T 
i 50 — r ^ — 
^ qM m r i M 
Antisense Sense CTL 
ODNs at 4 ^M 
Figure 3.28 Effect of antisense treatment on ATP content in HepG2 after 48 hr 
post incubation. 
5x105 HepG2 cells/well were seeded on 6-well plate and treated with oligonucleotides 
(ODNs):lipofectin (1:1) complex for 15 hr. After 48 hr post incubation, ATP assay 
was carried out. The cell pellet was resuspended in 12% TCA solution. ATP 
amount in the protein-free supernatant was determined by using a Sigma diagnostics 
kit while the TCA pellet was resuspended in 0.1% SDS with 1% IM NaOH. 
Besides, 5 of the SDS solution was used to determine the protein amount. The 
ATP concentration was then determined from an ATP standard curve. Finally, ATP 
content in cells was expressed as the ATP concentration (jiM) per protein content 
(mg). Data were expressed as the mean of triplicate samples 土 SD. The 
significance of the difference between the results of antisense treatment vs sense 
treatment was calculated by the Student's t-test (* p<0.05). Besides, the significance 
of the difference between the results of antisense treatment vs serum free treated 
control was calculated by the Student's t-test (# p<0.05). 
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Figure 3.29 Effect of antisense treatment on ATP content in HepG2 after 72 hr 
post incubation. 
5x105 HepG2 cells/well were seeded on 6-well plate and treated with oligonucleotides 
(ODNs):lipofectin (1:1) complex for 15 hr. After 72 hr post incubation, ATP assay 
was carried out. The cell pellet was resuspended in 12% TCA solution. ATP 
amount in the protein-free supernatant was determined by using a Sigma diagnostics 
kit while the TCA pellet was resuspended in 0.1% SDS with 1% IM NaOH. 
Besides, 5 i^l of the SDS solution was used to determine the protein amount. The 
ATP concentration was then determined from an ATP standard curve. Finally, ATP 
content in cells was expressed as the ATP concentration (|LIM) per protein content 
(mg). Data were expressed as the mean of triplicate samples 土 SD. The 
significance of the difference between the results of antisense treatment vs sense 
treatment was calculated by the Student's t-test (* p<0.05). Besides, the significance 
of the difference between the results of antisense treatment vs serum free treated 
control was calculated by the Student's t-test (# p<0.05). 
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Figure 3.30 Effect of antisense treatment on ATP content in R-HepG2 after 24 hr 
post incubation. 
6x105 R-HepG2 cells/well were seeded on 6-well plate and treated with 
oligonucleotides (ODNs):lipofectin (1:1) complex for 15 hr. After 24 hr post 
incubation, ATP assay was carried out. The cell pellet was resuspended in 12% TCA 
solution. ATP amount in the protein-free supernatant was determined by using a 
Sigma diagnostics kit while the TCA pellet was resuspended in 0.1% SDS with 1% 
IM NaOH. Besides, 5 |al of the SDS solution was used to determine the protein 
amount. The ATP concentration was then determined from an ATP standard curve. 
Finally, ATP content in cells was expressed as the ATP concentration OM) per 
protein content (mg). Data were expressed as the mean of triplicate samples ± SD. 
The significance of the difference between the results of antisense treatment vs sense 
treatment was calculated by the Student's t-test (* p<0.05). Besides, the significance 
of the difference between the results of antisense treatment vs serum free treated 
control was calculated by the Student's t-test (# p<0.05). 
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Figure 3.31 Effect of antisense treatment on ATP content in R-HepG2 after 48 hr 
post incubation. 
6x105 R-HepG2 cells/well were seeded on 6-well plate and treated with 
oligonucleotides (ODNs):lipofectin (1:1) complex for 15 hr. After 48 hr post 
incubation, ATP assay was carried out. The cell pellet was resuspended in 12% TCA 
solution. ATP amount in the protein-free supernatant was determined by using a 
Sigma diagnostics kit while the TCA pellet was resuspended in 0.1% SDS with 1% 
IM NaOH. Besides, 5 of the SDS solution was used to determine the protein 
amount. The ATP concentration was then determined from an ATP standard curve. 
Finally, ATP content in cells was expressed as the ATP concentration (j^M) per 
protein content (mg). Data were expressed as the mean of triplicate samples 土 SD. 
The significance of the difference between the results of antisense treatment vs sense 
treatment was calculated by the Student's t-test (* p<0.05). Besides, the significance 
of the difference between the results of antisense treatment vs serum free treated 
control was calculated by the Student's t-test (# p<0.05). 
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Figure 3.32 Effect of antisense treatment on ATP content in R-HepG2 after 72 hr 
post incubation. 
6x105 R-HepG2 cells/well were seeded on 6-well plate and treated with 
oligonucleotides (ODNs):lipofectin (1:1) complex for 15 hr. After 72 hr post 
incubation, ATP assay was carried out. The cell pellet was resuspended in 12% TCA 
solution. ATP amount in the protein-free supernatant was determined by using a 
Sigma diagnostics kit while the TCA pellet was resuspended in 0.1% SDS with 1% 
IM NaOH. Besides, 5 of the SDS solution was used to determine the protein 
amount. The ATP concentration was then determined from an ATP standard curve. 
Finally, ATP content in cells was expressed as the ATP concentration (fiM) per 
protein content (mg). Data were expressed as the mean of triplicate samples ± SD. 
The significance of the difference between the results of antisense treatment vs sense 
treatment was calculated by the Student's t-test (* p<0.05). Besides, the significance 
of the difference between the results of antisense treatment vs serum free treated 
control was calculated by the Student's t-test (# p<0.05). 
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3.1.8 Antisense oligonucleotides against Glut 2 exhibited antiproliferative effect 
on HepG2 and R-HepG2 cells 
Cell proliferation rate can be determined by monitoring the rate of incorporation 
of radioactive DNA precursors [methyl-^H] thymidine. The more radioactive 
labeled thymidine incorporation indicates that the cells grow more actively. First, 4 
I^ M antisense or sense oligonucleotides mixed with lipofectin in a ratio of 1:1 in 
serum free medium was added to cells and incubated at 37 for 15 hr transfection. 
After recovery from transfection at different time points (24 hr, 48 hr and 72 hr), 
tritium labeled thymidine incorporation assay was performed. Finally, the amount of 
thymidine incorporated into cells was measured by liquid scintillation counting. The 
significance of the difference between the results of antisense treatment vs sense 
treatment and serum free treated control were calculated by the Student's t-test. 
It was found that the amount of thymidine incorporated in antisense treated cells 
were significantly smaller (p-value < 0.05) than that in sense control and serum free 
treated control in 24 hr, 48 hr and 72 hr post incubation in HepG2 (figure 3.33 to 
3.35). After incubating with complete medium for 24 hr, the growth of cells was 
inhibited by 30% in antisense treatment. The antiproliferative effect was greater at 
48 hr post incubation and it was found to have 50% inhibition. For 72 hr post 
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incubation, the percentage of growth inhibition was lower when compared with those 
of 24 hr and 48 hr recovery period and was found to be 15%. 
For R-HepG2 cells, the uptake of thymidine in antisense treatment was lower 
compared with those of sense control and serum free treated control (figure 3.36 to 
3.38). Percentage of cell growth inhibition was 31% at 24 hr after transfection. 
The effect was more obvious at 48 hr post incubation and the antiproliferative effect 
after antisense treatment was found to be 60%. For 72 hr post incubation, the effect 
of antisense on thymidine uptake decreased when compared with those of 24 hr and 
48 hr post incubation and exhibited 18% growth inhibition. 
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Figure 3.33 Antiproliferative effect of Glut 2 antisense oligonucleotides on 
HepG2 cells at 24 hr post incubation. 
5x 104 HepG2 cells/well in 0.5ml complete medium were seeded on 24-well plate. 
Four |iM antisense or sense oligonucleotides (ODNs) and lipofectin complex in serum 
free medium was incubated with cells for 15 hr. After 24 hr post incubation in 
complete medium, tritium labeled thymidine incorporation assay was performed. 
First, 1 |LiCi [methyl-^H] thymidine in 0.5ml complete medium was added to cells to 
incubate at 37°C for 3 hr. Finally, cells were lysed and the amount of ^H-thymidine 
uptake was measured by a scintillation counter. Besides, volume of 5 |il cell lysate 
was used to determine the protein amount. Amount of ^H-thymidine incorporated 
was expressed as counts per minute (CPM)/ |Lig protein. Data were expressed as the 
mean of triplicate 土 SD. The significance of the difference between the results of 
antisense treatment vs sense treatment was calculated by the Student's t-test (* 
p<0.05). Besides, the significance of the difference between the results of antisense 
treatment vs serum free treated control was calculated by the Student's t-test (# 
p<0.05). 
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Figure 3.34 Antiproliferative effect of Glut 2 antisense oligonucleotides on 
HepG2 cells at 48 hr post incubation. 
5x 104 HepG2 cells/well in 0.5ml complete medium were seeded on 24-well plate. 
Four |liM antisense or sense oligonucleotides (ODNs) and lipofectin complex in serum 
free medium was incubated with cells for 15 hr. After 48 hr post incubation in 
complete medium, tritium labeled thymidine incorporation assay was performed. 
First, 1 i^Ci [methyl-^H] thymidine in 0.5ml complete medium was added to cells to 
incubate at TTC for 3 hr. Finally, cells were lysed and the amount of ^H-thymidine 
uptake was measured by a scintillation counter. Besides, volume of 5 j^ l cell lysate 
was used to determine the protein amount. Amount of ^H-thymidine incorporated 
was expressed as counts per minute (CPM)/ |Lig protein. Data were expressed as the 
mean of triplicate 土 SD. The significance of the difference between the results of 
antisense treatment vs sense treatment was calculated by the Student's t-test (* 
p<0.05). Besides, the significance of the difference between the results of antisense 
treatment vs serum free treated control was calculated by the Student's t-test (# 
p<0.05). 
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Figure 3.35 Antiproliferative effect of Glut 2 antisense oligonucleotides on 
HepG2 cells at 72 hr post incubation. 
5x 104 HepG2 cells/well in 0.5ml complete medium were seeded on 24-well plate. 
Four fiM antisense or sense oligonucleotides (ODNs) and lipofectin complex in serum 
free medium was incubated with cells for 15 hr. After 72 hr post incubation in 
complete medium, tritium labeled thymidine incorporation assay was performed. 
First, 1 |LiCi [methyl-^H] thymidine in 0.5ml complete medium was added to cells to 
incubate at 37�C for 3 hr. Finally, cells were lysed and the amount of ^H-thymidine 
uptake was measured by a scintillation counter. Besides, volume of 5 |LI1 cell lysate 
was used to determine the protein amount. Amount of ^H-thymidine incorporated 
was expressed as counts per minute (CPM)/ jig protein. Data were expressed as the 
mean of triplicate 土 SD. The significance of the difference between the results of 
antisense treatment vs sense treatment was calculated by the Student's t-test (* 
p<0.05). Besides, the significance of the difference between the results of antisense 
treatment vs serum free treated control was calculated by the Student's t-test (# 
p<0.05). 
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Figure 3.36 Antiproliferative effect of Glut 2 antisense oligonucleotides on 
R-HepG2 cells at 24 hr post incubation. 
6x 104 R-HepG2 cells/well in 0.5ml complete medium were seeded on 24-well plate. 
Four [iM antisense or sense oligonucleotides (ODNs) and lipofectin complex in serum 
free medium was incubated with cells for 15 hr. After 24 hr post incubation in 
complete medium, tritium labeled thymidine incorporation assay was performed. 
First, 1 fiCi [methyl-^H] thymidine in 0.5ml complete medium was added to cells to 
incubate at 37�C for 3 hr. Finally, cells were lysed and the amount of ^H-thymidine 
uptake was measured by a scintillation counter. Besides, volume of 5 jiil cell lysate 
was used to determine the protein amount. Amount of ^H-thymidine incorporated 
was expressed as counts per minute (CPM)/ |ag protein. Data were expressed as the 
mean of triplicate 土 SD. The significance of the difference between the results of 
antisense treatment vs sense treatment was calculated by the Student's t-test (* 
p<0.05). Besides, the significance of the difference between the results of antisense 
treatment vs serum free treated control was calculated by the Student's t-test (# 
p<0.05). 
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Figure 3.37 Antiproliferative effect of Glut 2 antisense oligonucleotides on 
R-HepG2 cells at 48 hr post incubation. 
6x 104 R_HepG2 cells/well in 0.5ml complete medium were seeded on 24-well plate. 
Four IliM antisense or sense oligonucleotides (ODNs) and lipofectin complex in serum 
free medium was incubated with cells for 15 hr. After 48 hr post incubation in 
complete medium, tritium labeled thymidine incorporation assay was performed. 
First，1 j^Ci [methyl-^H] thymidine in 0.5ml complete medium was added to cells to 
incubate at 37°C for 3 hr. Finally, cells were lysed and the amount of ^H-thymidine 
uptake was measured by a scintillation counter. Besides, volume of 5 jiil cell lysate 
was used to determine the protein amount. Amount of ^H-thymidine incorporated 
was expressed as counts per minute (CPM)/ jig protein. Data were expressed as the 
mean of triplicate 土 SD. The significance of the difference between the results of 
antisense treatment vs sense treatment was calculated by the Student's t-test (* 
p<0.05). Besides, the significance of the difference between the results of antisense 
treatment vs serum free treated control was calculated by the Student's t-test (# 
p<0.05). 
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Figure 3.38 Antiproliferative effect of Glut 2 antisense oligonucleotides on 
R-HepG2 cells at 72 hr post incubation. 
6x 104 R-HepG2 cells/well in 0.5ml complete medium were seeded on 24-well plate. 
Four |LIM antisense or sense oligonucleotides (ODNs) and lipofectin complex in serum 
free medium was incubated with cells for 15 hr. After 72 hr post incubation in 
complete medium, tritium labeled thymidine incorporation assay was performed. 
First，1 |LiCi [methyl-^H] thymidine in 0.5ml complete medium was added to cells to 
incubate at 37�C for 3 hr. Finally, cells were lysed and the amount of ^H-thymidine 
uptake was measured by a scintillation counter. Besides, volume of 5 |LI1 cell lysate 
was used to determine the protein amount. Amount of ^H-thymidine incorporated 
was expressed as counts per minute (CPM)/ j^ g protein. Data were expressed as the 
mean of triplicate 土 SD. The significance of the difference between the results of 
antisense treatment vs sense treatment was calculated by the Student's t-test (* 
p<0.05). Besides, the significance of the difference between the results of antisense 
treatment vs serum free treated control was calculated by the Student's t-test (# 
p<0.05). 
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3.1.9 Change in cell cycle pattern after antisense treatment 
It was found that Glut 2 antisense oligonucleotides could exert antiproliferative 
effect on HepG2 and R-HepG2 cells. Thus, it was interesting to find how did the 
antiproliferation of cells happen and it was wondered whether there was any changes 
in the cell cycle pattern after antisense treatment. First, 4 jiiM antisense or sense 
oligonucleotides mixing with lipofectin in a ratio of 1:1 in serum free medium was 
added to cells and incubated at 37 for 15 hr transfection. After recovery from 
transfection at different time points (24 hr, 48 hr and 72 hr), cell cycle analysis was 
performed. 
It was found that antisense treatment could affect the cell cycle pattern in both 
cell lines. Cells treated with Glut 2 antisense oligonucleotides had a lower 
proportion of cells in S phase than that in sense control and serum control. Besides, 
there was also an increase in the proportion of Gj phase after antisense treatment 
when compared with sense control and serum free control. The percentage of cells 
in G2+M phase was similar among the three experimental groups. 
After 24 hr post incubation, there was a slight change in the cell cycle pattern in 
the antisense treated HepG2 and R-HepG2 cells. There was 7.4% increase in G, 
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phase and 8.8% decrease in S phase in HepG2 cells (figure 3.39A). While in R-
HepG2 (figure 3.39B)，there was 8.9% increase in G, phase and 10.5% decrease in S 
phase when compared with serum free control. 
After 48 hr post incubation, significant changes in cell cycle pattern was 
observed. In HepG2 cells (figure 3.40A), there was 18% increase in proportion of 
cells in G! phase and 15.5% decrease in S phase after antisense treatment when 
compared with that in serum free control. Besides, 17% increase in G! phase and 
18.6% decrease in S phase was observed in antisense treated R-HepG2 cells (figure 
3.40B). However, after 72 hr post incubation, there was no observable change in 
cell cycle pattern in both HepG2 and R-HepG2 cells (figure 3.41). 
A pre-apoptotic peak in the cell cycle pattern should be found if the cells 
undergo apoptosis (figure 3.42). However, this pre-apoptotic peak was not detected 
after antisense treatment in both HepG2 and R-HepG2 cells after 24 hr, 48 hr and 72 
hr post incubation (figure 3.39-41). This indicated that treating the cells with Glut 2 
antisense oligonucleotides did not induce apoptosis. This was further confirmed by 
annexin-V-FITC and PI assay. 
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Figure 3.39 Cell cycle pattern of antisense treated HepG2 and R-HepG2 cells 
after 24 hr post incubation. 
5x 105 HepG2 cells or 6x 10' R-HepG2 cells in 2 ml complete medium were seeded 
on 6-well plate per well and incubated at 3 7 � C , 5 % CO2 overnight. Then, 
transfection was performed. After 24 hr post-incubation, the cells were used for cell 
cycle analysis. First, cells were resuspended in ice-cold 70% ethanol and stored at 4 
� C overnight. Then, cells were resuspended in 800 |il PBS, 100 jul RNase A (1 
mg/ml) and 20 |LI1 PI (2 mg/ml). The mixture was then incubated at 3 7 � C for 30 min. 
Cells were analyzed by using flow cytometry. 
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Figure 3.40 Cell cycle pattern of antisense treated HepG2 and R-HepG2 cells 
after 48 hr post incubation. 
5x 10^  HepG2 cells or 6x 10^  R-HepG2 cells in 2 ml complete medium were seeded 
on 6-well plate per well and incubated at 3 7 � C，5 % CO2 overnight. Then, 
transfection was performed. After 48 hr post-incubation, the cells were used for cell 
cycle analysis. First, cells were resuspended in ice-cold 70% ethanol and stored at 4 
� C overnight. Then, cells were resuspended in 800 PBS, 100 ]i\ RNase A (1 
mg/ml) and 20 PI (2 mg/ml). The mixture was then incubated at 3 7 � C for 30 min. 
Cells were analyzed by using flow cytometry. 
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Figure 3.41 Cell cycle pattern of antisense treated HepG2 and R-HepG2 cells 
after 72 hr post incubation. 
5x 105 HepG2 cells or 6x 10^  R-HepG2 cells in 2 ml complete medium were seeded 
on 6-well plate per well and incubated at 37 5 % CO� overnight. Then, 
transfection was performed. After 72 hr post-incubation, the cells were used for cell 
cycle analysis. First, cells were resuspended in ice-cold 70% ethanol and stored at 4 
°C overnight. Then, cells were resuspended in 800 PBS, 100 [xl RNase A (1 
mg/ml) and 20 |al PI (2 mg/ml). The mixture was then incubated at 3 7 � C for 30 min. 
Cells were analyzed by using flow cytometry. 
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Figure 3.42 Cell cycle pattern in apoptotic cells. 
A pre-apoptotic peak is found in the cell cycle analysis if the cells undergo apoptosis. 
Chapter 3 Results Page 131 
3.1.10 Glut 2 antisense oligonucleotides did not induce apoptosis 
In cell cycle analysis, it was found that there was no pre-apoptotic peak detected 
after antisense treatment. In order to further test whether antisense oligonucleotides 
against Glut 2 induced apoptosis, annexin-V-FITC and PI assay was performed. 
First, 4 )iM antisense or sense oligonucleotides mixing with lipofectin in a ratio of 1:1 
in serum free medium was added to cells and incubated at 3 7 � C for 15 hr transfection. 
After recovery from transfection at different time points (24 hr, 48 hr and 72 hr), 
annexin-V-FITC and PI assay was carried out. 
It was found that there was no significant change in the cell distribution among 
the four quadrants after antisense treatment in both HepG2 and R-HepG2 cells at 24 
hr, 48 hr and 72 hr post incubation (figure 3.43-45). The results indicated that Glut 2 
antisense oligonucleotides could suppress cell growth but they did not induce 
apoptosis in HcpG2 and R-HcpG2 cells. 
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Figure 3.43 Determination of apoptotic and necrotic cells after antisense 
treatment at 24 hr post incubation by annexin-V-FITC and PI assay. 
5x 105 HepG2 cells or 6x 10^  R-HepG2 cells in 2 ml complete medium were seeded 
on 6-well plate per well and incubated at 37 5 % CO2 overnight. Then, 
transfection was performed. After 24 hr post-incubation, the cells were used for 
annexin-V-FITC and PI assay. Both floating and adherent cells were collected. 
Adherent cells were collected after trypsinization. Then, the steps should be done in 
dark environment. Half million cells were loaded with 100 jul incubation buffer 
containing 2% (v/v) annexin-V-FITC and incubated for 20 min at room temperature. 
Cells were then loaded with 400 fil incubation buffer containing 2.5 |ag/ml PI and 
incubated at room temperature for further 20 min. Flow cytometric method was then 
used and signals of annexin-V-FITC and PI were collected. 
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Figure 3.44 Determination of apoptotic and necrotic cells after antisense 
treatment at 48 hr post incubation by annexin-V-FITC and PI assay. 
5x 105 HepG2 cells or 6x 10^  R-HepG2 cells in 2 ml complete medium were seeded 
on 6-well plate per well and incubated at 3 7 � C , 5 % CO2 overnight. Then， 
transfection was performed. After 48 hr post-incubation, the cells were used for 
annexin-V-FITC and PI assay. Both floating and adherent cells were collected. 
Adherent cells were collected after trypsinization. Then, the steps should be done in 
dark environment. Half million cells were loaded with 100 jul incubation buffer 
containing 2% (v/v) annexin-V-FITC and incubated for 20 min at room temperature. 
Cells were then loaded with 400 incubation buffer containing 2.5 ^g/ml PI and 
incubated at room temperature for further 20 min. Flow cytometric method was then 
used and signals of annexin-V-FITC and PI were collected. 
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Figure 3.45 Determination of apoptotic and necrotic cells after antisense 
treatment at 72 hr post incubation by annexin-V-FITC and PI assay. 
5x 10^  HepG2 cells or 6x 10^  R-HepG2 cells in 2 ml complete medium were seeded 
on 6-well plate per well and incubated at 3 7 � C , 5 % CO� overnight. Then, 
transfection was performed. After 72 hr post-incubation, the cells were used for 
annexin-V-FITC and PI assay. Both floating and adherent cells were collected. 
Adherent cells were collected after trypsinization. Then, the steps should be done in 
dark environment. Half million cells were loaded with 100 i^l incubation buffer 
containing 2% (v/v) annexin-V-FITC and incubated for 20 min at room temperature. 
Cells were then loaded with 400 i^l incubation buffer containing 2.5 jag/ml PI and 
incubated at room temperature for further 20 min. Flow cytometric method was then 
used and signals of annexin-V-FITC and PI were collected. 
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3.2 In vivo studies 
In vivo experiments were designed to investigate the effect of antisense 
oligonucleotide on a human tumor bearing animal model using nude mice. Firstly, 
HepG2 cells or R-HepG2 cells were inoculated subcutaneously into nude mice. 
Antisense treatment was started two days after implantation of cancer cells. Mice 
were sacrificed after successive five days antisense treatment. Then, tumor weight 
was measured and the effects of the drugs on normal tissues were assessed. In in 
vivo experiments, mice were divided into four groups: antisense or sense 
oligonucleotides treated group, saline group and negative control group (no treatment). 
There were seven nude mice in each group. The significance of difference between 
the results of antisense treated group vs sense and saline group were calculated by the 
Student's t-test. 
3.2.1 Effect of antisense oligonucleotides on the tumor weight in nude mice 
bearing HepG2 cells or R-HepG2 cells 
The tumors in nude mice were taken out and their weights were measured after 
antisense treatment. It was found that treating the mice with Glut 2 antisense 
oligonucleotides could reduce the tumor weight when compared with sense control 
and saline control groups in both HepG2 and R-HepG2 bearing nude mice. Figure 
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3.46 and 3.47 showed that tumor growth was suppressed by 42% and 53% in HepG2 
bearing mice and R-HepG2 bearing mice respectively when compared with that of the 
saline treated control. 
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Figure 3.46 Measurement of tumor weight after antisense treatment on HepG2 
bearing nude mice. 
4x 106 HepG2 cells in 0.2 ml PBS was inoculated subcutaneously (s.c.) into nude 
mouse and allowed it to grow for 2 days. Treatments were then started by injecting 
antisense or sense oligonucleotides at a dosage of 5 mg/kg/injection and saline by 
subcutaneously injection for successive five days. Mice were killed and the tumor 
weights were determined. Data were expressed as the mean of seven mice 土 SD. 
The significance of the difference between the results of antisense treatment vs sense 
treatment was calculated by the Student's t-test (* p<0.05). Besides, the significance 
of the difference between the results of antisense treatment vs saline treated control 
was calculated by the Student's t-test (# p<0.05). 
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Figure 3.47 Measurement of tumor weight after antisense treatment on R-HepG2 
bearing nude mice. 
4x 106 R-HepG2 cells in 0.2 ml PBS was inoculated subcutaneously (s.c.) into nude 
mouse and allowed it to grow for 2 days. Treatments were then started by injecting 
antisense or sense oligonucleotides at a dosage of 5 mg/kg/injection and saline by 
subcutaneously injection for successive five days. Mice were killed and the tumor 
weights were determined. Data were expressed as the mean of seven mice 土 SD. 
The significance of the difference between the results of antisense treatment vs sense 
treatment was calculated by the Student's t-test (* p<0.05). Besides, the significance 
of the difference between the results of antisense treatment vs saline treated control 
was calculated by the Student's t-test (# p<0.05). 
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3.2.2 Assessment of any side effect of antisense drug done on normal tissues of 
nude mice 
Anti-cancer drugs such as doxorubicin can cause heart damage when it is used 
on cancer patients. Thus, it is of clinical interest to investigate whether antisense 
treatment exhibits any side effects on normal tissues in tumor bearing nude mice. In 
general, measurement of serum creatine kinase (CK) and lactate dehydrogenase (LDH) 
and aspartate transaminase (AST) activities were used as a diagnostic tool to detect 
heart damage. Besides, liver injury was detected by determining plasma aspartate 
transaminase (AST) and alanine transaminase (ALT) activities. If there were any 
heart or liver damage, the enzymatic activities in plasma would elevate. 
3.2.2.1 Treatment on tumor bearing nude mice with Glut 2 antisense or sense 
oligonucleotides did not cause myocardial injury 
Plasma of nude mice in the four experimental groups were collected and used for 
enzymatic assays to detect if there was any side effect of antisense drugs on heart of 
tumor bearing nude mice. 
In HepG2 bearing nude mice, experimental results (figure 3.48) showed that CK 
activities were 312 U/L and 273 U/L in negative control groups and saline control 
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groups respectively. Besides, it was found that the enzymatic activities were lower 
in antisense and sense treated nude mice when compared with control groups. 
However, there was no significant difference between them. For LDH activity 
(figure 3.49), there was only a slight difference between the four experimental groups 
but no significant difference was found. Figure 3.50 showed that AST activities of 
antisense and sense treated nude mice were slightly higher than that in saline control 
and negative control groups. However, the p-value found was greater than 0.1 
indicating that there was no statistically significant difference between them. In 
conclusion, antisense or sense oligonucleotides were not harmful to the hearts of nude 
mice. 
In R-HepG2 bearing nude mice, it was found that there were differences in CK, 
LDH and AST activities (figure 3.51 to 3.53) between the four experimental groups. 
However, after calculating the p-value, it was found that there was no statistically 
significant difference between antisense or sense treated nude mice compared with the 
saline control and the negative control groups. These results implied that the drugs 
used did not cause myocardial injury in nude mice. 
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Figure 3.48 Effect of antisense drug on creatine kinase (CK) activity in plasma of 
HepG2 bearing nude mice. 
4x 106 HepG2 cells in 0.2 ml PBS was inoculated subcutaneously (s.c.) into nude 
mouse and allowed it to grow for 2 days. Treatments were then started by injecting 
antisense or sense oligonucleotides at a dosage of 5 mg/kg/injection and saline by 
subcutaneously injection for successive five days. Mice were killed and the plasma 
of nude mice was collected. CK activity was measured using an enzyme assay kit. 
Data were expressed as the mean of seven mice 土 SD. 
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Figure 3.49 Effect of antisense drug on lactate dehydrogenase (LDH) activity in 
plasma of HepG2 bearing nude mice. 
4x 106 HepG2 cells in 0.2 ml PBS was inoculated subcutaneously (s.c.) into nude 
mouse and allowed it to grow for 2 days. Treatments were then started by injecting 
antisense or sense oligonucleotides at a dosage of 5 mg/kg/injection and saline by 
subcutaneously injection for successive five days. Mice were killed and the plasma 
of nude mice was collected. LDH activity was measured using an enzyme assay kit. 
Data were expressed as the mean of seven mice 土 SD. 
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Figure 3.50 Effect of antisense drug on aspartate transaminase (AST) activity in 
plasma of HepG2 bearing nude mice. 
4x 106 HepG2 cells in 0.2 ml PBS was inoculated subcutaneously (s.c.) into nude 
mouse and allowed to grow for 2 days. Treatments were then started by injecting 
antisense or sense oligonucleotides at a dosage of 5 mg/kg/injection and saline by 
subcutaneously injection for successive five days. Mice were killed and plasma of 
nude mice was collected. AST activity was measured using an enzyme assay kit. 
Data were expressed as the mean of seven mice 土 SD. 
Chapter 3 Results Page 144 
g 300 — 
250 " i " 
t 200 - P ] p L , - t - i — 
三 三 三 d 
CD 
S 0 """"""‘~ ‘ — — ‘ “ — — 
Negative Saline Antisense Sense 
control control 
Treatment 
Figure 3.51 Effect of antisense drug on creatine kinase (CK) activity in plasma of 
R-HepG2 bearing nude mice. 
4x 10^  R-HepG2 cells in 0.2 ml PBS was inoculated subcutaneously (s.c.) into nude 
mouse and allowed to grow for 2 days. Treatments were then started by injecting 
antisense or sense oligonucleotides at a dosage of 5 mg/kg/injection and saline by 
subcutaneously injection for successive five days. Mice were killed and plasma of 
nude mice was collected. CK activity was measured using an enzyme assay kit. 
Data were expressed as the mean of seven mice 土 SD. 
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Figure 3.52 Effect of antisense drug on lactate dehydrogenase (LDH) activity in 
plasma of R-HepG2 bearing nude mice. 
4x 10' R-HepG2 cells 
in 0.2 ml PBS was inoculated subcutaneously (s.c.) into nude 
mouse and allowed to grow for 2 days. Treatments were then started by injecting 
antisense or sense oligonucleotides at a dosage of 5 mg/kg/injection and saline by 
subcutaneously injection for successive five days. Mice were killed and plasma of 
nude mice was collected. LDH activity was measured using an enzyme assay kit. 
Data were expressed as the mean of seven mice 土 SD. 
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Figure 3.53 Effect of antisense drug on aspartate transaminase (AST) activity in 
plasma of R-HepG2 bearing nude mice. 
4x 106 R-HepG2 cells in 0.2 ml PBS was inoculated subcutaneously (s.c.) into nude 
mouse and allowed to grow for 2 days. Treatments were then started by injecting 
antisense or sense oligonucleotides at a dosage of 5 mg/kg/injection and saline by 
subcutaneously injection for successive five days. Mice were killed and plasma of 
nude mice was collected. AST activity was measured using an enzyme assay kit. 
Data were expressed as the mean of seven mice 土 SD. 
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3.2.2.2 Liver injury was not detected in Glut 2 antisense or sense oligonucleotides 
treated tumor bearing nude mice 
In order to determine if there was any side effect of antisense drugs on liver, 
plasma of nude mice in the four experimental groups were collected and used for AST 
and ALT enzymatic assays. 
It was found that there was a similar effect of antisense drugs on plasma AST 
activity of HepG2 bearing nude mice (figure 3.50) when compared with the saline 
control and negative control. Moreover, ALT activities of antisense or sense treated 
groups were lower than that of the control groups (figure 3.54). However, there was 
no statistically significant difference between them after calculating the p-value using 
the Student's t-test. 
Figure 3.53 shows that the activities of AST were approximately the same in the 
four experimental groups of R-HepG2 bearing nude mice. For ALT activity (figure 
3.55), it was found that the activities were higher in antisense and sense treated nude 
mice when compared with those of the controls. Since the p-value was greater than 
0.1, there was no statistically significant difference between the four experimental 
groups. In conclusion, antisense drugs did not cause liver injury on HepG2 and R-
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HepG2 bearing mice as the enzymatic activities of plasma AST and ALT were similar 
among the four groups. 
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Figure 3.54 Effect of antisense drug on alanine transaminase (ALT) activity in 
plasma of HepG2 bearing nude mice. 
4x 106 HepG2 cells in 0.2 ml PBS was inoculated subcutaneously (s.c.) into nude 
mouse and allowed it to grow for 2 days. Treatments were then started by injecting 
antisense or sense oligonucleotides at a dosage of 5 mg/kg/injection and saline by 
subcutaneously injection for successive five days. Mice were killed and the plasma 
of nude mice was collected. ALT activity was measured using an enzyme assay kit. 
Data were expressed as the mean of seven mice 土 SD. 
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Figure 3.55 Effect of antisense drug on alanine transaminase (ALT) activity in 
plasma of R-HepG2 bearing nude mice. 
4x 106 R-HepG2 cells in 0.2 ml PBS was inoculated subcutaneously (s.c.) into nude 
mouse and allowed it to grow for 2 days. Treatments were then started by injecting 
antisense or sense oligonucleotides at a dosage of 5 mg/kg/injection and saline by 
subcutaneously injection for successive five days. Mice were killed and the plasma 
of nude mice was collected. ALT activity was measured using an enzyme assay kit. 
Data were expressed as the mean of seven mice 土 SD. 
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Chapter 4 Discussion 
4.1 In vitro study of the effect of antisense oligonucleotides against 
Glut 2 on HepG2 and its multi-drug resistant R-HepG2 cell lines 
Antisense oligonucleotides (ODNs) are now widely employed in elucidating 
genetic control as well as in therapeutic applications (Alama et al., 1997). Antisense 
oligonucleotide is short, negatively charged single stranded DNA which is 
complementary to a target mRNA sequence. After hybridization to the target 
sequences by Watson-Crick base pairing, antisense oligonucleotides can block the 
translation process and thus prevent the expression of the targeted gene. 
In this project, two cells lines were used, HepG2 and its multi-drug resistant R-
HepG2 cells. When comparing the toxic effect of different anti-cancer drugs 
(doxorubicin, vincristine and methotrexate) on both cell lines, it was found that the 
IC50 of R-HepG2 cells developed in our laboratory increased significantly when 
compared with the parental HepG2 cells (Chan et al., 2000). Thus, it is a multi-drug 
resistant cell line. The drug resistance was probably due to the expression of P-
glycoprotein which was responsible for pumping out drugs using energy provided by 
ATP, so that the intracellular accumulation of drug decreased. It was found that the 
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amount of doxorubicin retained in HepG2 cells was twice as much as that of the R-
HepG2 cells (figure 3.5). 
In fact, the antisense oligonucleotide approach has two advantages over 
conventional drugs (Agrawal, 1996): (1) the mRNA of the disease target gene has a 
defined sequence, (2) the antisense oligonucleotide interacts with the target gene by 
Watson-Crick base pairing, providing specificity and affinity. In chemotherapy, 
some drugs such as doxorubicin exert side effects on other tissues such as heart and 
liver. However, the specificity of antisense sequence to a particular gene can 
eliminate or reduce side effects on normal cells. Besides, development of drug 
resistance after prolonged treatment will not occur when antisense oligonucletoides 
are used. Antisense oligonucleotides can also block mRNA translation and intervene 
before a protein is formed. 
Thus, antisense oligonucleotides can also provide another approach for treatment 
of multi-drug resistant tumor cells which are no longer sensitive to chemotherapy any 
more after prolonged treatment. 
Glucose transporter genes are overexpressed in many human cancer cells 
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(Yamamoto et al” 1990) in order to provide extra energy for the rapid growth of 
cancer cells. In hepatoma, overexpression of Glut 1-3 was found. In this project, 
antisense oligonucleotides were designed against Glut 2. It is because Glut 1 is 
found in all body cells so as to provide basal glucose requirement while Glut 3 is 
responsible for providing energy for the brain and essential for brain function. Thus, 
Glut 1 and Glut 3 were not the target genes as suppression of these two glucose 
transporters will cause damage to other normal tissues. The side effects on other 
tissues should be lesser for using antisense against Glut 2 as Glut 2 exists in fewer 
tissues types, namely hepatocytes, pancreatic beta cells, intestine and kidney. Thus, 
in the project, the effects of antisense oligonucleotides against glucose transporter 2 in 
human hepatoma HepG2 and its multi-drug resistant R-HepG2 cells were studied. 
4.1.1 Design of antisense oligonucleotides against Glut 2 
Complete cDNA sequence of human glucose transporter 2 was searched from 
GenBank in NCBI homepage (http://www.ncbi.nlm.nih.gov/entrez). Then, 15 base 
pairs oligonucleotide was chosen within the coding region. The sequence specificity 
was checked by using the program ‘Blast search' in GenBank to find out whether the 
sequence chosen was homologous to any human gene. The sequence could be used 
if no match with other human cDNA sequences was found. Thus, it was believed 
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that antisense oligonucleotides designed against that part of the target gene would not 
hybridize to any other DNA strand within the cells and did not produce non-specific 
antisense effects. Besides, control oligonucleotides (sense oligonucleotides) were 
needed. 
4.1.2 Conditions for antisense inhibition by oligonucleotides 
There are two limitations on the application of antisense oligonucleotides in in 
vitro studies: instability and low efficiency of cellular uptake of oligonucleotides. 
Since unmodified antisense oligonucleotides were subjected to nuclease degradation, 
modification to oligonucleotides was necessary to make them more resistant to 
nuclease in medium. The most commonly used and commercially available 
modified oligonucleotides were phosphorothioated oligonucleotides, which were used 
in this project. It was found that phosphorothioated oligonucleotides were more 
stable than the unmodified ones in cytoplasmic extract and human serum (Akhtar et 
al, 1991). Besides, phosphorothioated oligonucleotides can be recognized and 
cleaved by RNase H. After degradation of the target mRNA, bound oligonucleotides 
were released and bound to another mRNA. Thus, one antisense 
oligodeoxynucleotide can mediate the RNase H-dependent cleavage of many target 
mRNA transcripts (Lima et al., 1997, Cooper et al., 1999). 
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Plasma membranes of living cells restrict the transportation of large and 
negatively charged molecules. Thus, this membrane would act as a barrier for 
polyanionic molecules such as oligonucleotides. However, uptake efficiency could 
be improved and enhanced by using a carrier system, lipofectin reagent which was 
composed of cationic lipid N-[l-(2，3-dioleyloxy)propyl]-n，n,n-trimethylammonium 
chloride (DOTMA), and dioleoyl phosphotidylethanolamine (DOPE). Positive 
charges on lipofectin could interact with the negative charges on the sulfur atoms of 
oligonucleotides to form complex. However, results showed that lipofectin reagent 
was toxic to HepG2 and R-HepG2 cells when it was used at a high concentration and 
a long incubation time. Besides, uptake assays were carried out to investigate the 
efficiency of the carrier system (lipofectin reagent) and flow cytometry was used to 
monitor cellular uptake of FITC-labeled phosphorothioated oligonucleotides against 
Glut 2. It was found that the lipofectin reagent could greatly enhance the uptake of 
oligonucleotides in HepG2 and R-HepG2 cells when compared with that when 
oligonucleotides was used alone (figure 3.9 and figure 3.10). Thus, lipofectin could 
ensure a successful delivery of antisense oligonucleotides into cells. Since the 
greatest amount of oligonucleotide was taken up by cells in 15 hr transfection time 
and lipofectin toxicity was relatively low at 15 hr incubation in both cell types, the 
transfection time was set to be 15 hr for both cell lines under the considerations of 
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efficacy of oligonucleotide uptake and toxicity of lipofectin. 
After uptake of oligonucleotides, antisense oligonucleotides would then take 
action by binding to the target sequence. Thus, post-incubation was required after 
15 hr transfection so as to allow antisense to take effect. In this project, we were 
interested to investigate the effect of antisense treatment after different post 
incubation periods (24 hr, 48 hr, 72 hr). Twenty-four hours incubation time was 
chosen as the shortest incubation period in the study because it took time for the 
oligonucleotides to bind to the target sequence and time was required for the 
oligonucleotides to produce effect. Besides, it was suggested by the user manual of 
lipofectin (GIBCO BRL) that assays should be performed at 48-72 hr post 
transfection. 
Cell viability after antisense treatment was investigated by MTT assay. It was 
found that Glut 2 antisense oligonucleotide was effective in inhibiting the growth of 
HepG2 and R-HepG2 cells and the antisense effect was in a dose dependent manner 
(figure 3.12 — figure 3.17). When a greater concentration of antisense was used, the 
greater was the effect on cell viability. However, effect of sense control was also 
great at high concentration. This might be due to the non-specific effect of sense 
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oligonucleotides and the great amount of lipofectin used at high oligonucleotide 
concentration as oligonucleotides were mixed with lipofectin in a 1:1 (w/w) ratio. 
The non-specific effect was mainly due to the binding of sense oligonucleotides to a 
wide range of proteins in sequence independent manner that would be toxic to cells 
(Wagner, 1994). Thus, it was preferable to use a lower concentration of 
oligonucleotides with certain effectiveness. The antisense concentration was set to 
be 4 |LIM at which there was approximately 80% viable cells in the sense control at 24, 
48 and 72 hr post incubation. In conclusion, the conditions for antisense 
oligonucleotides against Glut 2 on HepG2 and R-HepG2 cells were found to be 4 |LIM 
and the transfection time was 15 hr. 
4.1.3 Biological effects of antisense oligonucleotides 
After determining the conditions for antisense treatment, biological effects of 
antisense oligonucleotides on both HepG2 and R-HepG2 cells were studied in order to 
find out whether Glut 2 antisense oligonucleotides could exert anti-tumor effect on 
both cell lines. 
In this project, the main purpose of using antisense oligonucleotides was to 
inhibit translation of the selected gene and ultimately suppress protein expression of 
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Glut 2 in both HepG2 and R-HepG2 cells. By Western Blot analysis, it was found 
that expression of Glut 2 in protein level decreased after antisense treatment. The 
suppression of Glut 2 increased from 24 hr post incubation to 48 hr post incubation. 
However, the effect of antisense seemed to recover 72 hr after transfection (figure 
3.18 and figure 3.19). The percentage of Glut 2 protein suppression was found to be 
43% and 37% in HepG2 and R-HepG2 respectively when compared with that of 
serum free control at 48 hr post incubation. Thus, Glut 2 antisense oligonucleotides 
were effective in suppressing protein expression of Glut 2 in both cell lines. It was 
also determined that protein expression of Glut 1 was significantly lowered (about 
46% suppression) in antisense treated murine blastocyst (Chi et aL, 2000). Besides, 
antisense oligonucleotides targeted to human and murine Stat6 was found to be active 
in inhibiting Stat6 protein expression by 40-50% (Hill et al., 1999). In the present 
study, effect of antisense that was not so obvious at 72 hr post incubation was 
probably due to the beginning of degradation of antisense oligonucleotides inside the 
cells (Crooke et al., 1995). Some findings suggested that the effect of antisense 
inhibition lasted between 24 and 48 hr, depending on the cell line used (Dean et al., 
1994，McKay et al., 1996 and Copper et al., 1999). It was also suggested that the 
antisense effect produced by antisense oligonucleotides was transient and the effect 
was observed within 36 hr after oligonucleotides uptake (Chan et al., 1999). Thus, 
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in order to inhibit the expression of protein with long half-life, repeated 
oligonucleotide transfections might be required (Copper et al” 1999). 
Since the protein expression level of Glut 2 was suppressed after antisense 
treatment, the transport capacity of this transporter would be affected. Thus, it was 
thought that Glut 2 mediated glucose transport would also be reduced. In order to 
verify this, the activity of Glut 2 after antisense treatment was measured by using 2-
Deoxy-D-[l-^H] glucose uptake assay. In both HepG2 and R-HepG2 cells, amount 
of glucose uptake was lower than that in sense treated and serum free treated controls 
at different post transfection periods with the greatest effect observed at 48 hr post 
incubation. At that time point, Glut 2 antisense oligonucleotides could reduce 
glucose uptake in HepG2 and R-HepG2 at 54% and 45% respectively (figure 3.21 and 
figure 3.24). Thus, glucose uptake was reduced after the suppression of Glut 2 
protein expression level. Other findings suggested that glucose uptake was 
significantly reduced (up to 80%) after treating the NKN45 cells with antisense 
against Glut 1 (Noguchi et al., 2000). Besides, it was found that decrease in protein 
expression of Glut 1 after antisense treatment correlated with a significant decrease in 
glucose uptake in murine blastocysts (Chi et al., 2000). However, at 72 hr post 
incubation, antisense effect started to recover and protein expression level of Glut 2 
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after antisense treatment were similar to that observed in serum free control in both 
HepG2 and R-HepG2 cells in the present study. Subsequently, percentage of glucose 
uptake reduction was lower at 72 hr post incubation with 16% and 15% reduction in 
HepG2 and R-HepG2 respectively when compared with serum free control (figure 
3.22 and figure 3.25). Effect of antisense that began to recover at 72 hr post 
incubation was probably due to the degradation of oligonucleotides (Crooke et al., 
1995). Besides, it was found that the effect of antisense inhibition lasted for between 
24 and 48 hr, depending on the cell line used (Dean et al, 1994, McKay et al., 1996 
and Copper et aL, 1999). 
Cancer cells show increased glucose uptake and utilization when compared with 
their non-malignant counterparts (Holroyde et aL, 1981). This may be due to their 
high proliferation rate (Grover et al., 1998). Increased glucose uptake can be 
achieved by expressing more glucose transporter genes. Since malignant cells 
depend mainly on glucose for energy supply and for growth, upset of Glut activity by 
antisense oligonucleotides decreased glucose uptake and would subsequently affect 
the ATP production in cells. In order to verify this, ATP amounts in cells after 
treatment were determined. It was found that ATP content in both HepG2 and R-
HepG2 cells were decreased by 55% and 48% respectively at 48 hr post incubation 
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after Glut 2 antisense treatment when compared with serum free control and the effect 
was the greatest at that time point (figure 3.28 and figure 3.31). This decrease in 
ATP amount might be due to the decrease in glucose transport after suppression of 
Glut 2 as some findings suggested that decreased glucose transport and utilization 
resulted in the decrease of ATP production (Chi et al,, 2000). The decrease in ATP 
amount in cells may slow down the growth rate of cells as lesser energy was supplied 
for proliferation as it was found that reduced cell viability was closely related to the 
fall in ATP required for cell growth (Marmor et al., 1996). However, the detailed 
action mechanism leading to antiproliferation was still unknown. In the present 
study, both glucose uptake and ATP content in antisense treated HepG2 and R-HepG2 
cells was lower when compared with that of the controls. The antisense effect 
increased from 24 hr to 48 hr post incubation and started to recover at 72 hr post 
incubation. These results matched with the pattern of expression level of Glut 2 
protein after antisense treatment. 
From thymidine incorporation assay, it was found that Glut 2 antisense 
oligonucleotides exert anti-proliferative effect on hepatoma. In antisense treated 
HepG2 and R-HepG2 cells, the growth rate was slower when compared with the sense 
and serum free controls after 24 hr, 48 hr and 72 hr post incubation with the greatest 
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effect observed 48 hr after transfection. Antisense oligonucleotides at 48hr post 
incubation could inhibit cell growth of HepG2 and R-HepG2 by up to 50% and 60% 
respectively when compared with that of the serum free control (figure 3.34 and 
figure 3.37). Other findings indicated that the use of antisense against Glut 1 
suppressed tumor growth in MKN45 cells (Noguchi et al., 2000) and HL-60 cells 
(Chan et al., 1999). Besides, it was suggested that glucose was essential for 
proliferation (Greiner et al., 1994). 
It was found that antisense treated cells had significant changes in the cell cycle 
pattern. A decrease in the number of cells in the synthesis phase and an increase in 
the number of cells in the G, phase (figure 3.39-3.41) with the greatest effect was 
observed at 48 hr post incuabiton: (i) in HepG2 cells, 18% increase in proportion of 
cells in G! phase and 15.5% decrease in S phase and (ii) in R-HepG2 cells, 17% 
increase in Gi phase and 18.6% decrease in S phase. This result was in accord with 
a previous study that treating MKN45 cells with Glut 1 antisense oligonucleotides 
could lead to changes in cell cycle pattern (Noguchi et al., 2000). 
Glut 2 antisense oligonucleotides could exert anti-proliferative effect on HepG2 
and R-HepG2 cells but they did not induce apoptosis as no pre-apoptotic peak was 
Chapter 4 Discussion Page 164 
detected and no changes in the cells distribution among the four quadrants in annexin-
V-FITC and PI assay could be observed after antisense treatment (figure 3.43-3.45). 
Similar finding was detected in treating MKN45 cells with Glut 1 antisense 
olignucleotides that no apoptosis was found after antisense treatment (Noguchi et al., 
2000). The sequence of antisense oligonucleotides exerted effect on both cell lines 
were summarized (figure 4.1). 
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In HepG2 and R-HepG2 cells, after antisense treatment: 
Suppression of Glut 2 protein level 
Y 
Decrease in glucose uptake 
Y 
Lowering of ATP content 
Y 
Slow down the growth of cells and change the cell cycle pattern 
but no induction of apoptosis 
Antisense effects increased from 24 hr post incubation to 48 hr post incubation and 
began to decrease after 72 hr post incubation. 
Figure 4.1 Summary of the antisense effect on HepG2 and R-HepG2 cells. 
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4.2 In vivo study of the effect of antisense oligonucleotides against 
Glut 2 on HepG2 or R-HepG2 cells bearing nude mice 
Actually, the physiological conditions in HepG2 and R-HepG2 cells in cell 
culture are quite different from that observed in liver cancer. Clinically, liver cancer 
is a solid tumor in which the blood vessels are severely deformed and thus cannot 
supply enough oxygen for the fasting growing tumor cells leading to hypoxia. As a 
result, tumor cells mainly depend on glycolysis to generate ATP as the energy source. 
However, only two molecules ATP are generated per mole of glucose through 
glycolysis. Besides, malignant cells are known to exhibit a high rate of glycolysis 
even under aerobic conditions (Eigenbrodt et al., 1985, Marmor et al,, 1996). Thus, 
an increased uptake of glucose provides energy to enhance cell synthesis and ensure a 
high glycolytic capacity (Eigenbrodt et al, 1985). Glycolysis was found to be the 
primary energy source in tumor cells, exceeding the capacity of mitochondrial 
oxidative energy metabolism (Eigenbrodt et al., 1985, Beckner et al., 1990, Fiechter 
and Gmunder, 1989 and Greiner et al, 1994). This might be an important aspect of 
malignant transformation and uncontrolled cell growth. On the other hand, in cell 
culture, hypoxia does not occur as the cells were cultured in incubator supplied with 
oxygen. But for in vivo studies, after inoculation of tumor cells in nude mice 
subcutaneously, solid tumor was formed. Thus, the physiological conditions of our 
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animal models are similar to that of solid tumor in liver. 
4.2.1 Effect of Glut 2 antisense oligonucleotides on tumor weight 
After investigating the antisense effect in cells, it was interesting to apply Glut 2 
antisense oligonucleotides to in vivo models and study their effects as it was an 
important preliminary step for application of antisense oligonucleotides in clinical 
trials. 
After inoculation of HepG2 or R-HepG2 cells into nude mice, a dosage of 5 
mg/kg/injection antisense or sense oligonucleotides was injected subcutaneously into 
each nude mouse for successive 5 days. It was found that tumor growth was 
suppressed in antisense oligonucleotides treated experimental group. Tumor weight 
was suppressed by 42% and 53% in HepG2 bearing mice and R-HepG2 bearing mice 
respectively when compared with that of the saline control group (figure 3.46 and 
figure 3.47). Thus, Glut 2 antisense oligonucleotides used in in vivo models were 
effective in inhibiting tumor growth. Besides, other finding also indicated that the 
growth rate of tumors treated with antisense Glut 1 in nude mice was significantly 
slower (Noguchi et al., 2000). Moreover, tumor weight in nude mice bearing human 
pancreatic cancer cell line, BxPC-3 xenografts, treated with antisense against gastrin 
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was significantly reduced by 54% when compared with control and the use of 
antisense oligonucleotides to gastrin could inhibit growth of human pancreatic cancer 
(Smithed al, 1999). 
4.2.2 In vivo side effects of oligonucleotides 
The in vivo side effects of phosphorothioated oligonucleotides may be the result 
of their polyanionic nature, length, base composition and sequence or be due to their 
metabolites (Agrawal et al” 1996). 
Studies carried out in mice and rats showed that phosphorothioated 
oligonucleotides were well tolerated. However, dose-dependent side effects were 
observed in rats after daily administration of oligonucleotides. They included 
splenomegaly, thrombocytopenia and elevation of the levels of liver enzymes 
aspartate transaminase (AST) and alanine transaminase (ALT) (Sarmiento et al., 
1994). The severity of these side effects was dependent on the dose and the 
frequency and duration of dosing. These side effects might be sequence dependent. 
However, additional data were required to confirm that. 
In this project, toxic effects of antisense on other tissues were investigated by 
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determining the plasma creatine kinase (CK), lactate dehydrogenase (LDH), aspartate 
transaminase (AST) and alanine transaminase (ALT). It was certain that antisense 
phosphorothioated oligonucleotides against Glut 2 administered for successive five 
days at the dosage of 5 mg/kg/injection did not cause damage to tissues such as heart, 
liver, kidney and skeletal muscle as the plasma enzymatic levels of CK, LDH, AST 
and ALT after antisense treatment were similar to those observed in the sense and 
saline control as well as those in the negative control (figure 3.48 — figure 3.55). 
Thus, the treatment schedule employed in this study was quite effective with no side 
effects on organs such as the heart, the liver and the kidney. 
4.3 Conclusion 
Human hepatocellular carcinoma occurs in over half a million of people, and 
China has the biggest incidence in the world. Besides, liver cancer is the second 
most common cause of cancer death in both China and Hong Kong. Thus, it is an 
urgent matter to find ways to cure this type of cancer. 
Antisense oligonucleotides complementary to specific mRNA sequence are 
widely used as gene expression inhibitor both in vitro and in vivo. Besides, some 
antisense treatments are even under clinical trials now. In the present study, Glut 2 
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antisense oligonucleotides were designed and used to downregulate the expression of 
Glut 2 in hepatoma HepG2 and its multi-drug resistant R-HepG2 cells. Our findings 
suggested that the protein level of Glut 2 was suppressed and subsequently, reduction 
of glucose uptake was determined. Finally, ATP amount in cells was reduced as a 
result of the reduction of glucose transporter 2 activity. Besides, antisense 
oligonucleotides against Glut 2 could exert antiproliferative effect on both cell lines 
by changing the cell cycle pattern. However, antisense treatment did not induce 
apoptosis. On the other hand, application of Glut 2 antisense oligonucleotides in 
tumor bearing nude mice was effective in suppressing tumor growth and no side effect 
was detected in tissues such as heart, liver and kidney. Thus, the effect of antisense 
oligonucleotides was promising both in vitro and in vivo. However, further studies 
have to be carried out to determine the detailed mechanism leading to antiproliferative 
effect of antisense treatment. 
In the present study, it was found that the greatest effect of Glut 2 antisense 
oligonucleotides on proliferation of HepG2 and R-HepG2 cells were about 50% and 
60% growth inhibition respectively while tumor growth was suppressed by 40% -
50% in tumor bearing nude mice. Glut 2 antisense oligonucleotides could not 
suppress cell growth completely because of the existence of other glucose transporter 
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isoforms, Glut 1 and Glut 3, for glucose transport. Thus, it is of great interest to 
study the combined treatment of antisense against both Glut 1 and Glut 2 as Glut 1 is 
important in providing the basal glucose needed in cells and is overexpressed in many 
human malignant cells. Thus, in future, further studies can be performed to test 
whether combined treatment of antisense oligonucleotides against both Glut 1 and 
Glut 2 exerts a synergistic effect on the proliferation of both cell lines as a high degree 
of Glut 1 expression has been reported in human hepatocellular carcinoma, whereas 
very little Glut 1 mRNA was found in normal liver cells (Su et al., 1990). In in vivo 
studies, targeting the antisense oligonucleotides to specific cancer cells without 
affecting other normal cells is an important matter as Glut 1 exists in almost all cell 
types. Since the antisense effect is only effective for a short period of time and the 
effect began to recover at 72 hr post transfection, repeated oligonucleotide 
transfection can be carried out. Besides, it was found that antisense effect was 
greater and lasted for a longer time in plasmid-derived antisense RNA against glucose 
Glut 1 treated HL-60 cells (Chan et al., 1999). Thus, plasmid-derived antisense 
RNA against glucose transporter gene can be used in order to enhance the efficiency 
of the antisense treatment. 
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